

BMJ Open Defining timeliness in care for patients with lung cancer: a scoping review

Adnan Ansar ^{1,2}, Virginia Lewis ^{1,3}, Christine Faye McDonald ^{2,4,5},
Chaojie Liu ⁶, Muhammad Aziz Rahman^{2,3,7,8,9}

To cite: Ansar A, Lewis V, McDonald CF, *et al.* Defining timeliness in care for patients with lung cancer: a scoping review. *BMJ Open* 2022;**12**:e056895. doi:10.1136/bmjopen-2021-056895

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-056895>).

Received 07 September 2021
Accepted 11 March 2022

ABSTRACT

Objectives Early diagnosis and reducing the time taken to achieve each step of lung cancer care is essential. This scoping review aimed to examine time points and intervals used to measure timeliness and to critically assess how they are defined by existing studies of the care seeking pathway for lung cancer.

Methods This scoping review was guided by the methodological framework for scoping reviews by Arksey and O'Malley. MEDLINE, EMBASE, CINAHL and PsycINFO electronic databases were searched for articles published between 1999 and 2019. After duplicate removal, all publications went through title and abstract screening followed by full text review and inclusion of articles in the review against the selection criteria. A narrative synthesis describes the time points, intervals and measurement guidelines used by the included articles.

Results A total of 2113 articles were identified from the initial search. Finally, 68 articles were included for data charting process. Eight time points and 14 intervals were identified as the most common events researched by the articles. Eighteen different lung cancer care guidelines were used to benchmark intervals in the included articles; all were developed in Western countries. The British Thoracic Society guideline was the most frequently used guideline (20%). Western guidelines were used by the studies in Asian countries despite differences in the health system structure.

Conclusion This review identified substantial variations in definitions of some of the intervals used to describe timeliness of care for lung cancer. The differences in healthcare delivery systems of Asian and Western countries, and between high-income countries and low-income-middle-income countries may suggest different sets of time points and intervals need to be developed.

BACKGROUND

Lung cancer is the most common cancer, with an incidence of 2.1 million globally during 2018, and is the most frequent cause of deaths in both sexes in 14 regions of the world.¹ Incidence and mortality vary across countries due to differences in smoking prevalence and other risk factors, but overall survival rates are low globally (5year survival of 10%–20% in most countries) with most patients diagnosed at an advanced stage.¹

Timely diagnosis and access to effective treatment are important determinants of

Strengths and limitations of this study

- This scoping review documented the commonly studied time points in the lung cancer care pathway and the heterogeneity in naming the intervals and, guidelines adopted in the disease care pathway for lung cancer across different studies.
- Arksey and O'Malley's five-stage scoping review framework and Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was followed for this scoping review.
- This study was informed by a previously published protocol which dictated a transparent and rigorous search strategy for four databases.
- Quality of studies was not assessed.
- Only studies published in English were included in the review, which may miss potential literature in other languages.

outcome in patients with cancer.² Higher cancer survival rates are evident in high performing healthcare systems. For example, patients with lung cancer in Japan (33%), Israel (27%) and Korea (25%) have a much higher 5-year survival rate than their counterparts in India, Thailand, Brazil and Bulgaria (all less than 10%).³ Early diagnosis can improve survival and reduce lung cancer mortality through timely initiation of treatment.⁴

Numerous studies have been conducted to assess timeliness of initiation and completion of cancer treatment. However, the pathway to cancer diagnosis and treatment is complex.⁵ The patient journey from onset of symptoms to initiation of treatment involves multiple stages, which vary significantly across different health systems,⁶ with different health systems having different 'bottlenecks' in the patient journey.

The patient journey can be categorised into different care time points. Time points are the landmarks or events that take place in a patient journey to healthcare, for example, onset of symptom(s), contact with a healthcare provider, referral, diagnosis, initiation of treatment, and so on. Depending on the



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Adnan Ansar;
ansar.a@students.latrobe.edu.au

outcome of interest of a research or intervention, intervals are defined by calculating the time between two agreed time points. Timeliness can be defined as reaching different time points of care in a way that supports the best patient outcomes. It usually starts from the date of onset of symptoms and ends at the date of initiation of treatment. Guidelines can be defined as a set of agreed recommendation that aim to streamline the process in each step of the disease care pathway to set routine or standard clinical practice. In some countries, clinical guidelines have been developed to establish a maximal length requirement for the intervals between different time points to ensure optimal patient care outcomes. These have enabled measurement of delay. However, studies describing time intervals often mislabeled these intervals as ‘delays’ despite a lack of benchmarking, creating confusion among readers. There are also marked variations in the definitions of these intervals across studies, and in how the data were obtained, measured and presented.⁷ This ambiguity leads readers to make assumptions about the interpretation of the terms and findings. Moreover, due to differences in health systems, studies are seldom comparable across countries.⁶ Referral pathways vary between countries. For example, in some developing countries, all the diagnostic tests required to diagnose a cancer are completed before a patient is referred to a specialist, thus contributing to variation in the definition and length of the diagnostic segment in the care pathway between such developing countries and the developed country which was the source of the guidance.

Existing guidelines for lung cancer care vary in the benchmarks or cut-off values used to describe acceptable limits of time for each step in the disease care pathway. As a result, definitions and measures of ‘timeliness of care’ vary across countries. Furthermore, the majority of guidelines were developed in Western countries, considering country-specific resources and healthcare mechanisms, and associated with effective referral systems governed by policies.⁸ It is unlikely that guidelines developed for Western health systems can be fully effective in poorly resourced health systems,^{8,9} which require different definitions, measurements and guidelines for timely care compatible with their available resources and the strength of their health systems.¹⁰

Several models were proposed in an attempt to improve consistency in the definition, classification and measurement of timeliness of care, but the models are not devoid of limitations. These include the Andersen model of total patient delay,¹¹ the model of pathways to treatment¹² and the Aarhus statement.⁶ Andersen’s model can capture the decisional and behavioural processes that occur before the initiation of treatment, but is limited in its capacity to address the complex and dynamic journey into and through the healthcare system.¹² The subsequently proposed ‘Model of pathways to treatment’ is a descriptive framework which can encompass the psychological theories with a focus on patient factors in the appraisal and help-seeking intervals. The most recent and widely

accepted framework, ‘The Aarhus Statement,’¹³ proposes a universal framework to incorporate the issue of lack of consensus in definitions and methods across studies conducted on timeliness of cancer care. It defines four important time points that links different interval durations with patient outcomes to determine targets and guidelines (date of first symptom, date of first presentation to a general practitioner (GP), date of referral and date of diagnosis). It also provides guidance on how to design research with greater precision and transparency. All these models provide an overarching framework that can be adapted to different system contexts. This scoping review aimed to examine time points and intervals used to measure timeliness and to critically assess and compare how they are defined by existing studies of the care seeking pathway for lung cancer.

METHODS

This scoping review followed the methodological framework for scoping reviews by Arksey and O’Malley¹⁴ which was further enhanced by Levac *et al*¹⁵ and the Joanna Briggs Institute.¹⁶ Stages of the scoping review framework included (1) Identifying the research question, (2) Identifying relevant studies, (3) Study selection, (4) Charting the data and (5) Collating, summarising, and reporting the results. The University of York Centre for Reviews and Dissemination guidance for undertaking reviews in health care¹⁷ and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist¹⁸ were followed to ensure the comprehensiveness of the review. This scoping review categorised available definitions and terminologies relating to timeliness in the disease care pathway, without an intention of achieving consensus.

Identifying the research question

To address the aim of assessing definitions describing timeliness of seeking and receiving care in patients with lung cancer in published articles, the following research questions were posed:

1. What are the time points and intervals commonly identified in the care pathway for lung cancer in the existing literature?
2. How is timeliness of seeking and receiving care for lung cancer described and related to guidelines in the existing literature?
3. Are there differences in definitions, measurements and benchmarking of timeliness used in Western and Asian countries?

Identifying relevant studies

The study population of included literature was patients with diagnosed lung cancer, irrespective of histological type and disease stage. Studies were identified through the keywords that were used to describe timeliness of seeking care, time points in seeking care and intervals between time points in the disease care pathway. Studies were excluded if timeliness of care or time points and intervals

in the care pathway were ambiguous, were not specific for lung cancer, if the primary focus of the article was not timeliness of care, if the articles were not published in English, or if studies were published only as abstracts. This scoping review included all studies, irrespective of study methodology, quality and publication type to gain a better understanding of how researchers have operationalised and measured timeliness of seeking and receiving care for lung cancer in various study settings between May 1999 and May 2019.

The text contained in the titles and abstracts of the papers from the initial search and the keywords used to describe those articles were used to formulate the search strategies specific to the selected databases. MEDLINE, EMBASE, PsycINFO and CINAHL were searched for published articles. An academic health sciences librarian was consulted on selecting the appropriate keywords and the most appropriate MeSH terms and filters to maximise inclusion of articles within the search, and how to modify them for selected bibliographic databases (full search strategy in online supplemental file 1). Reference lists were screened for relevant articles. Search results were imported into EndNote (V.X9) to organise search results specific to each database and later used to generate the reference list for the review. References were imported to Covidence, which was used for documenting the process including duplicate identification and removal, title and abstract screening, and full-text review for included articles. Detailed keywords mapping and database specific search strategies were published in the protocol of this scoping review.¹⁹

Study selection

Selection of publications involved two stages. First, title and abstract were screened against the inclusion criteria, and second, the potentially relevant papers went through full-text review. To increase the reliability of the decision process all selected papers were independently assessed by at least two researchers. Due to the exploratory nature of this scoping review, a detailed methodological quality assessment was not required.²⁰ One author (AA) performed a search of the electronic database for literature. Two authors (AA and AR) independently reviewed and screened the abstracts of the searched articles for inclusion. The other two authors (VL and CFM) reviewed the disagreements and resolved by discussion with all the authors.

Data charting, collating and summarising

A data extraction chart was used to capture the data from selected articles (online supplemental file 2), which was recorded on Microsoft Excel 365. Data were extracted by AA independently and examined by authors (VL, CL, CFM and AR).

Initially a coding tree was constructed which had three levels: time points as the first level, time intervals (with starting and ending time point) as the second level, and timeliness (with a definition or benchmarking) as the

third level. The initial coding tree was further expanded and divided when new categories emerged from data. An exhaustive list of time points related to seeking or receiving care on the patient care journey was extracted through comparing and merging similar terminologies. The sequence of the time points was determined as follows, (1) patient recalled onset of symptoms, (2) first contact with a healthcare provider, (3) diagnosis, (4) referral to a specialist, (5) first visit to a specialist/hospital admission, (6) patient informed about diagnosis, (7) pre-initiation of treatment, and (8) initiation of treatment. Afterwards, we summarised and charted the type of intervals examined in the included studies. Intervals in the lung cancer patient care pathway considered the duration between one time point and another time point. Relevant definitions or measurements in relation to the three level coding themes (time points, intervals and timeliness) were also extracted with or without further verification from the cited guidelines. The data on definition of interval or delay were extracted when an article explicitly mentioned the guiding principle (cancer care guideline or self-definition) which included researcher/study constructed definitions as well. Comparisons between Asian and Western countries were based on the similarities or differences in using time points, intervals and measurement of timelines for intervals.

RESULTS

A total of 2113 articles were identified from the initial search. After duplicates removal, 1546 articles were screened for eligibility and 269 articles were selected for full-text review. Two hundred and one articles were excluded because they were not relevant, only published as abstract or not related to lung cancer. Finally, 68 articles were included for the data charting process (figure 1).




Figure 1 PRISMA flow chart. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Table 1 Characteristics of included articles

N=68	Characteristics of included articles	N (%)
Year of publication	2001–2010	25 (37)
	2011–2018	43 (63)
Study setting*	North America (USA, Canada)	21 (30.88)
	UK (England, Scotland, Wales and Northern Ireland)	15 (22.06)
	Europe (Denmark, Netherlands, Norway, Spain, Italy, Sweden, France, Poland, Finland)	13 (19.12)
	Asia (Turkey, India, Mainland China, Taiwan, Nepal)	9 (13.24)
	Australia and New Zealand	8 (11.76)
Study design	Cross-sectional	41 (60.83)
	Other study designs	13 (19.1)
	Cohort	9 (13.2)
	Case control	3 (4.4)
	Systematic review	1 (1.5)
	Scoping review	1 (1.5)
Sample size	Range	12–171 208
	All studies total	280591

*Review papers not counted in study settings and sample size.

Characteristics of the included articles are given in [table 1](#) (review articles were excluded).

Time points

Based on the selected articles, time points were classified and the sequence was determined into eight categories ([table 2](#)). Commonly mentioned time points included onset of symptom(s), first contact with healthcare provider, diagnosis/first suspicious investigation result, referral/receipt of referral by a specialist (at secondary care), first visit to a specialist/hospital admission, patient informed of lung cancer diagnosis and initiation of treatment.

Intervals

Fourteen different intervals, from onset of symptom(s) to initiation of treatment were identified in this scoping review ([table 3](#)): (1) From onset of symptoms to first contact with healthcare provider, (2) From first contact with general healthcare provider to first contact with specialist healthcare provider, (3) From first contact with secondary/tertiary healthcare provider to diagnosis, (4) From first contact with healthcare provider to diagnosis, (5) From diagnosis to contact with secondary/tertiary healthcare provider, (6) From onset of symptoms to contact with secondary/tertiary healthcare provider, (7) From contact with secondary/tertiary healthcare

provider to initiation of treatment, (8) From onset of symptom(s) to referral to a specialist/ receipt of referral by a specialist or thoracic department, (9) From referral to a specialist/ receipt of referral by a specialist or thoracic department to diagnosis, (10) From onset of symptom to diagnosis, (11) From referral to a specialist/ receipt of referral by a specialist or thoracic department to treatment, (12) From first contact with healthcare provider to treatment, (13) From diagnosis to initiation of treatment and (14) From onset of symptom to Initiation of treatment. Intervals were not measured as completion of treatment or death.

Some articles used different terminologies to label the same intervals; and similarly, the same terminology was used to label different intervals in different articles.

1. From onset of symptoms to first contact with healthcare provider interval: patient delay^{21–26} and patient's application interval.^{27 28}
2. Duration from first contact with healthcare provider to first contact with specialist at secondary care or next level: GP delay,^{21 23–25} GP interval,²⁹ primary care interval,³⁰ referral delay^{21 23 25} and referral interval.^{27 28}
3. From first contact with secondary or tertiary healthcare provider to diagnosis interval: specialist interval,²⁹ specialist's delay (second doctor's delay),^{21 24 25} diagnosis delay³¹ and diagnosis interval.²⁸
4. From first contact with healthcare provider to diagnosis: diagnostic interval^{29 30 32 33} and delay in diagnosis.³⁴
5. From diagnosis to contact with secondary/tertiary healthcare provider: referral interval in one study.³⁵
6. Interval between onset of symptom to contact with secondary/tertiary healthcare provider: patient delay.³⁶
7. Interval between contact with secondary/tertiary healthcare provider and initiation of treatment: hospital delay^{25 31} and treatment interval.³⁵
8. From onset of symptoms to referral to a specialist thoracic department: referral delay,³⁷ specialist delay.³¹
9. From referral to a specialist or receipt of referral by a specialist or thoracic department to diagnosis: referral interval.³⁰
10. Interval between onset of symptom to diagnosis: total diagnostic delay²⁹ and time to diagnosis.³⁸
11. From referral to a specialist/receipt of referral by a specialist or thoracic department to treatment interval: time to treatment (hospital delay)³⁹ and delay in secondary healthcare.²²
12. Interval between first contact with healthcare provider to treatment: healthcare interval,³⁰ system delay²² and doctor's interval.^{27 28}
13. From diagnosis to initiation of treatment: therapeutic delay,²³ treatment delay,^{22 31} treatment interval,^{30 33} system interval,⁴⁰ pretreatment interval,³² diagnosis-to-treatment delay⁴¹ and diagnosis-to-treatment interval.⁴²

Table 2 Time points in the lung cancer care pathway

Time points	Articles	Definition of time point	Settings
Onset of symptoms	Baughan <i>et al</i> UK ⁸⁰	Date patient first noticed symptoms	UK
	Corner <i>et al</i> UK ⁹⁴	The date, week, or month when a symptom or health change was recalled, and actions taken as a result by the patient were recorded as well as a description of the health change or symptom	
	Dobson <i>et al</i> UK ⁹⁵	The date of symptom onset was defined as the first symptom reported	
	Melling <i>et al</i> UK ⁸⁴	First symptom reported by the patients to their GPs	
	Neal <i>et al</i> UK ⁹⁶	Onset of first symptom	
	Smith <i>et al</i> Scotland ⁹⁷	The date participant defined first symptom	
	Salomaa <i>et al</i> Finland ²¹	The dates of onset of symptoms	
	Yang <i>et al</i> Mainland China ⁹⁸	First symptom	
	Yilmaz <i>et al</i> Turkey ²⁷	Date of initial symptoms	
First contact with healthcare provider	Özlü <i>et al</i> Turkey ⁶⁹	Onset of symptoms	Europe
	Baughan <i>et al</i> UK ⁸⁰	Date patient of first presentation with a GP	UK
	Corner <i>et al</i> UK ⁹⁴	Timing of first visit to the GP	
	Dobson <i>et al</i> UK ⁹⁵	Date on which person consulted a GP about their symptoms.	
	Smith <i>et al</i> Scotland ⁹⁷	Date of presentation to a medical practitioner	
	Melling <i>et al</i> UK ⁸⁴	Presentation of the first cancer symptom to the GP	
	Neal <i>et al</i> UK ⁹⁶	First presentation (Face-to-face consultations, nurse consultations, telephone consultations) to primary care	
	Vidaver <i>et al</i> USA ⁶⁸	First visit to primary healthcare provider	
	Helsper <i>et al</i> 2017 Netherlands ³⁰	First contact (physical or telephone) with the GP for suspected cancer-related signs or symptoms	
	Salomaa <i>et al</i> Finland ²¹	First visit to a doctor, who was in general, a GP	
	Rankin <i>et al</i> Australia ³²	First consultation with primary healthcare provider	
	Largey <i>et al</i> Australia ⁹⁹	Dates of first presentation as the time point the clinician started investigation or referral for possible investigation	North America
	Yang <i>et al</i> Mainland China ⁹⁸	First contact with local doctor	
	Yilmaz <i>et al</i> Turkey ²⁷	Date of first doctor visit	
	Özlü <i>et al</i> Turkey ⁶⁹	First presentation to a physician	
Diagnosis/first suspicious investigation result	Corner <i>et al</i> UK ⁹⁴	Date of diagnosis (the investigation procedure was not specified)	UK
	Neal <i>et al</i> UK ⁹⁶	Date of diagnosis (CT/PET scan, a tissue diagnosis)	
	Melling <i>et al</i> UK ⁸⁴	Date of Diagnosis (bronchoscopy, mediastinoscopy, CT scan, bone scan, plural cytology)	
	Vidaver <i>et al</i> USA ⁶⁸	First imaging result with a lung abnormality	
	Singh <i>et al</i> USA ⁶⁵	Earliest date that a diagnostic clue could have been recognised by a care provider	
	Li <i>et al</i> Canada ¹⁰⁰	Date of diagnosis	
	Maiga <i>et al</i> USA ⁴²	Date of pathology diagnosis	
	Schultz <i>et al</i> USA ⁷⁰	Date when a pathologic diagnosis of lung cancer was confirmed	
	Grunfeld <i>et al</i> Canada ⁸³	Date of confirmed diagnosis (date of the pathology or radiology report)	
	Helsper <i>et al</i> Netherlands ³⁰	Date of the histological confirmation of the primary tumour	Europe
	Rankin <i>et al</i> Australia ³²	Time of the formal cancer diagnosis being made	
	Largey <i>et al</i> Australia ⁹⁹	Date of histological diagnosis	
	Malalasekera <i>et al</i> 2018 Australia ³³	First suspicious investigation report (the investigation procedure was not specified)	
	Özlü <i>et al</i> Turkey ⁶⁹	Date of histopathological diagnosis	
	Yang <i>et al</i> Mainland China ²²	Date of diagnosis (CT scan and biopsy)	Asia
	Yilmaz <i>et al</i> Turkey ²⁷	Date of diagnosis	
Referral to a specialist/ receipt of referral by a specialist or thoracic department	Baughan <i>et al</i> UK ⁸⁰	Date of decision to refer by primary care	UK

Continued

Table 2 Continued

Time points	Articles	Definition of time point	Settings
	Melling <i>et al</i> UK ⁸⁴	Date of referral to secondary care	North America
	Neal <i>et al</i> UK ⁹⁶	Date of GP referral to specialist or admission to hospital	
	Grunfeld <i>et al</i> Canada ⁸³	Referral for diagnostic assessment was received by the consultant	
	Vidaver <i>et al</i> USA ⁶⁸	Date of referral to a specialist	
	Helsper <i>et al</i> Netherlands ³⁰	The time point when the responsibility for the patient was transferred from a GP to secondary care	Europe
	Salomaa <i>et al</i> Finland ²¹	The date of the writing of the referral requesting consultation from a specialist	
	Stokstad <i>et al</i> Norway ⁸⁷	A referral letter for suspected lung cancer was received by the Department of Thoracic Medicine	
	Largey <i>et al</i> Australia ⁹⁹	Date of referral by primary healthcare provider	Australia and New Zealand
	Malalasekera <i>et al</i> Australia ³³	Date of first referral to secondary care	
	Yang <i>et al</i> Mainland China ²²	Date of referral to hospital from primary physician	Asia
First visit to a specialist/ Hospital admission	Baughan <i>et al</i> UK ⁸⁰	Date patient first seen by specialist	UK
	Vidaver <i>et al</i> USA ⁶⁸	First visit to a specialist	North America
	Salomaa <i>et al</i> Finland ²¹	The first appointment with the specialist	Europe
	Largey <i>et al</i> Australia ⁹⁹	First specialist visit	Australia and New Zealand
	Malalasekera <i>et al</i> 2018 Australia ³³	First specialist visit	
	Alexander <i>et al</i> 2016 Australia ⁷⁶	Date of first medical oncology or haematology review for patients with an urgent presentation	Asia
	Yilmaz <i>et al</i> 2008 Turkey ²⁷	Date of admission to pneumology department	
Patient informed of the cancer diagnosis	Baughan <i>et al</i> 2009 UK ⁸⁰	Date patient told the diagnosis	UK
	Grunfeld <i>et al</i> 2009 Canada ⁸³	Date patient informed of diagnosis	North America
	Vidaver <i>et al</i> 2016 USA ⁶⁸	Date patient informed of the biopsy result	
Pre-initiation of treatment	Maiga <i>et al</i> USA ⁴²	<ul style="list-style-type: none"> ► Date of lung nodule identification on CT imaging according to the medical record ► Date when a lung nodule originally less than 10 mm in size was documented as having new growth on CT imaging. 	North America
Initiation of treatment	Melling <i>et al</i> UK ⁸⁴	Date treatment started (surgery, radical radiotherapy with chemotherapy).	UK
	Li <i>et al</i> Canada ¹⁰⁰	Date of first treatment, surgery and adjuvant treatment	North America
	Shugarman <i>et al</i> USA ⁶⁶	First date recorded for treatment (surgery, radiation, or chemotherapy)	
	Vidaver <i>et al</i> USA ⁶⁸	First treatment date	
	Grunfeld <i>et al</i> Canada ⁸³	Date of initiation of neoadjuvant chemotherapy, surgery if no preoperative treatment was required, chemotherapy, radiotherapy, or a decision not to treat.	
	Maiga <i>et al</i> USA ⁴²	Time of resection.	Europe
	Stokstad <i>et al</i> Norway ⁸⁷	The time for treatment decision as the date when such a decision was documented in the Electronic Medical Record	
	Helsper <i>et al</i> Netherlands ³⁰	Date of start of therapy as registered in the Network of Cancer Registries	
	Iachina <i>et al</i> Denmark ⁸⁵	First day of treatment is defined as the date of initiation of surgical, oncological, or radiological treatment, whichever comes first	
	Alexander <i>et al</i> Australia ⁷⁶	Time to chemotherapy should be measured from the date that chemotherapy treatment was decided. For adjuvant chemotherapy, time to chemotherapy should be measured from the date of surgery.	Australia and New Zealand
	Evans <i>et al</i> Australia ⁷⁷	Date of initial definitive management	
	Malalasekera <i>et al</i> Australia ³³	Treatment start date	
	Rankin <i>et al</i> Australia ³²	Start of treatment	
	Özlü <i>et al</i> Turkey ⁶⁹	Start of treatment	Asia
	Yang <i>et al</i> Mainland China ²²	Initiation of treatment date	
	Yilmaz <i>et al</i> Turkey ²⁷	Date of thoracotomy	

GP, general practitioner.

Table 3 Intervals in the lung cancer care pathway

Intervals	Articles	Study setting
From onset of symptoms To First contact with healthcare provider	Baughan <i>et al</i> UK ⁸⁰	UK
	Corner <i>et al</i> UK ⁹⁴	
	Neal <i>et al</i> UK ⁹⁶	
	Smith <i>et al</i> Scotland ⁹⁷	
	Brocken <i>et al</i> Netherlands ²³	Europe
	Helsper <i>et al</i> Netherlands ³⁰	
	Koyi <i>et al</i> Sweden ²⁴	
	Salomaa <i>et al</i> Finland ²¹	
	Sawicki <i>et al</i> Poland ¹⁰¹	
	Rolke <i>et al</i> Norway ²⁵	
From first contact with secondary/tertiary healthcare provider To diagnosis	Ezer <i>et al</i> Canada ⁸¹	North America
	Ellis and Vandermeer Canada ⁴³	
	Verma <i>et al</i> Australia ¹⁰²	Australia and New Zealand
	Thapa <i>et al</i> Nepal ²⁶	Asia
	Yang <i>et al</i> Mainland China ⁴¹	
	Yilmaz <i>et al</i> Turkey ²⁷	
	Özlü <i>et al</i> Turkey ⁶⁹	
	Sulu <i>et al</i> Turkey ²⁸	
	Forrest <i>et al</i> UK ⁷⁸	UK
	Baughan <i>et al</i> UK ⁸⁰	
From first contact with general healthcare provider To First contact with specialist healthcare provider	Barrett and Hamilton 2008 UK ¹⁰³	
	Devbhandari <i>et al</i> UK ⁷¹	
	Melling <i>et al</i> UK ⁸⁴	
	Girolamo <i>et al</i> UK ⁷⁹	
	Rolke <i>et al</i> Norway ²⁵	Europe
	Hueto Pérez De Heredia <i>et al</i> Spain ⁷²	
	Koyi <i>et al</i> Sweden ²⁴	
	Helsper <i>et al</i> Netherlands ³⁰	
	Salomaa <i>et al</i> Finland ²¹	
	Brocken <i>et al</i> Netherlands ²³	
From diagnosis to contact with secondary/ tertiary healthcare provider	Vidaver <i>et al</i> USA ⁶⁸	North America
	Olsson <i>et al</i> USA ¹⁰⁴	
	Ellis and Vandermeer Canada ⁴³	
	Grunfeld <i>et al</i> Canada ⁸³	

Continued

Table 3 Continued

Intervals	Articles	Study setting
From onset of symptoms To First contact with healthcare provider	Verma <i>et al</i> Australia ¹⁰²	Australia and New Zealand
	Emery <i>et al</i> Australia ²⁹	
	Sood <i>et al</i> New Zealand ⁷³	
	Yilmaz <i>et al</i> Turkey ²⁷	Asia
	Thapa <i>et al</i> Nepal ²⁶	
	Sulu <i>et al</i> Turkey ²⁸	
	Salomaa <i>et al</i> Finland ²¹	Europe
	Rolke <i>et al</i> Norway ²⁵	
	Koyi <i>et al</i> Sweden ²⁴	
	Gonzalez <i>et al</i> Spain ³¹	
From first contact with secondary/tertiary healthcare provider To diagnosis	Ellis and Vandermeer Canada ⁴³	North America
	Emery <i>et al</i> Australia ²⁹	Australia and New Zealand
	Sulu <i>et al</i> Turkey ²⁸	Asia
	Özlü <i>et al</i> Turkey ⁶⁹	
	Barrett and Hamilton UK ¹⁰³	UK
	Corner <i>et al</i> UK ⁹⁴	
	Devbhandari <i>et al</i> UK ⁷¹	
	Forrest <i>et al</i> UK ⁷⁸	
	Neal <i>et al</i> UK ⁹⁶	
	Helsper <i>et al</i> Netherlands ³⁰	Europe
From first contact with general healthcare provider To First contact with specialist healthcare provider	Ezer <i>et al</i> Canada ⁸¹	North America
	Vidaver <i>et al</i> USA ⁶⁸	
	Emery <i>et al</i> Australia ²⁹	Australia and New Zealand
	Rankin <i>et al</i> Australia ³²	
	Özlü <i>et al</i> Turkey ⁶⁹	Asia
	Hsieh <i>et al</i> Taiwan ³⁴	
	Kanarek <i>et al</i> USA ³⁵	North America
	Wai <i>et al</i> Canada ¹⁰⁵	
	Winget <i>et al</i> Canada ¹⁰⁶	
	Zullig <i>et al</i> USA ¹⁰⁷	
From diagnosis to contact with secondary/ tertiary healthcare provider	Bjerager <i>et al</i> Denmark ¹⁰⁸	Europe
	Ampil <i>et al</i> USA ³⁶	North America
	Thapa <i>et al</i> Nepal ²⁶	Asia

Continued

Table 3 Continued

Intervals	Articles	Study setting
From contact with secondary/tertiary healthcare provider To initiation of treatment	Devbhandari <i>et al</i> UK ⁸⁶	UK
	Girolamo <i>et al</i> UK ⁷⁹	
	Gonzalez <i>et al</i> Spain ³¹	Europe
	Rolke <i>et al</i> Norway ²⁵	
	Hueto Pérez De Heredia <i>et al</i> Spain ⁷²	
	Hubert <i>et al</i> Canada ¹⁰⁹	North America
	Kanarek <i>et al</i> USA ³⁵	
	Winget <i>et al</i> Canada ¹⁰⁶	
	Vidaver <i>et al</i> USA ⁶⁸	
	Ellis and Vandermeer Canada ⁴³	
	Ampil <i>et al</i> USA ³⁶	
	Olsson <i>et al</i> USA ¹⁰⁴	
	Wai <i>et al</i> Canada ¹⁰⁵	
	Verma <i>et al</i> Australia ¹⁰²	Australia and New Zealand
From onset of symptoms to referral to specialist/ receipt of referral by a specialist or thoracic department	Lee <i>et al</i> UK ⁷⁴	UK
	Gonzalez <i>et al</i> Spain ³¹	Europe
	Buccheri and Ferrigno Italy ³⁷	
From referral to a specialist/ receipt of referral by a specialist or thoracic department to diagnosis	Barrett and Hamilton UK ¹⁰³	UK
	Smith <i>et al</i> Scotland ⁹⁷	
	Helsper <i>et al</i> Netherlands ³⁰	Europe
	Grunfeld <i>et al</i> Canada ⁸³	North America
	Evans <i>et al</i> Australia ⁷⁷	Australia and New Zealand
	Largey <i>et al</i> Australia ⁶⁷	
	Sood <i>et al</i> New Zealand ⁷³	
From onset of symptoms to diagnosis	Corner <i>et al</i> UK ⁹⁴	UK
	Lee <i>et al</i> UK ⁷⁴	
	Walter <i>et al</i> UK ³⁸	
	Koyi <i>et al</i> Sweden ²⁴	Europe
	Wai <i>et al</i> Canada ¹⁰⁵	North America
	Emery <i>et al</i> Australia ²⁹	Australia and New Zealand
	Sachdeva <i>et al</i> India ⁸⁸	Asia
	Chandra <i>et al</i> India ⁴¹	
	Dubey <i>et al</i> India ⁸⁹	

Continued

Table 3 Continued

Intervals	Articles	Study setting
From referral to a specialist/ receipt of referral by a specialist or thoracic department to treatment	Devbhandari <i>et al</i> UK ⁷¹	UK
	Smith <i>et al</i> Scotland ⁹⁷	
	Forrest <i>et al</i> UK ⁷⁸	
	Bozcuk and Martin UK ³⁹	
	Iachina <i>et al</i> Denmark ⁸⁵	Europe
	Olsson <i>et al</i> USA ¹⁰⁴	North America
	Grunfeld <i>et al</i> Canada ⁸³	
	Ampil <i>et al</i> USA ³⁶	
	Evans <i>et al</i> Australia ⁷⁷	Australia and New Zealand
	Largey <i>et al</i> Australia ⁶⁷	
	Sood <i>et al</i> New Zealand ⁷³	
	Yang <i>et al</i> Mainland China ²²	Asia
From first contact with healthcare provider to treatment	Melling <i>et al</i> UK ⁸⁴	UK
	Helsper <i>et al</i> Netherlands ³⁰	Europe
	Sawicki <i>et al</i> Poland ¹⁰¹	
	Vidaver <i>et al</i> USA ⁶⁸	North America
	Ezer <i>et al</i> Canada ⁸¹	
	Yang <i>et al</i> Mainland China ²²	Asia
	Yilmaz <i>et al</i> Turkey ²⁷	
	Özlü <i>et al</i> Turkey ⁶⁹	
	Sulu <i>et al</i> Turkey ²⁸	
From diagnosis to initiation of treatment	Forrest <i>et al</i> . 2014 UK ⁷⁸	UK
	Brocken <i>et al</i> Netherlands ²³	Europe
	Gonzalez <i>et al</i> Spain ³¹	
	Salomaa <i>et al</i> Finland ²¹	
	Helsper <i>et al</i> Netherlands ³⁰	
	Iachina <i>et al</i> Denmark ⁸⁵	
	Schultz <i>et al</i> USA ⁷⁰	North America
	Kanarek <i>et al</i> USA ³⁵	
	Grunfeld <i>et al</i> Canada ⁸³	
	Borrayo <i>et al</i> USA ¹¹⁰	
	Kim <i>et al</i> Canada ⁴⁰	
	Olsson <i>et al</i> USA ¹⁰⁴	
	Ost <i>et al</i> USA ⁷⁵	
	Yorio <i>et al</i> USA ¹¹¹	
	Zullig <i>et al</i> USA ¹⁰⁷	
	Li <i>et al</i> Canada ¹⁰⁰	
	Maiga <i>et al</i> USA ⁴²	
	Vidaver <i>et al</i> USA ⁶⁸	

Continued

Table 3 Continued

Intervals	Articles	Study setting
	Winget <i>et al</i> Canada ¹⁰⁶	
	Largey <i>et al</i> Australia ⁶⁷	Australia and New Zealand
	Malalasekera <i>et al</i> Australia ³³	
	Evans <i>et al</i> Australia ⁷⁷	
	Rankin <i>et al</i> Australia ³²	
	Özlü <i>et al</i> Turkey ⁶⁹	Asia
	Yang <i>et al</i> Mainland China ²²	
	Yilmaz <i>et al</i> Turkey ²⁷	
	Sulu <i>et al</i> Turkey ²⁸	
	Chandra <i>et al</i> 2009 India ⁴¹	
From onset of symptoms to initiation of treatment	Salomaa <i>et al</i> Finland ²¹	Europe
	Koyi <i>et al</i> Sweden ²⁴	
	Rolke <i>et al</i> Norway ²⁵	
	Sawicki <i>et al</i> Poland ¹⁰¹	
	Ellis and Vandermeer Canada ⁴³	North America
	Olsson <i>et al</i> USA ¹⁰⁴	
	Verma <i>et al</i> Australia ¹⁰²	Australia and New Zealand
	Yilmaz <i>et al</i> Turkey ²⁷	Asia
	Özlü <i>et al</i> Turkey ⁶⁹	
	Sulu <i>et al</i> Turkey ²⁸	
	Chandra <i>et al</i> India ⁴¹	

14. From onset of symptom(s) to initiation of treatment: global delay,⁴³ total delay²⁵ and symptom to treatment delay.⁴¹

Table 4 presents the time intervals commonly studied in the included articles. The most frequently studied interval was ‘diagnosis to initiation of treatment’, followed by ‘first contact with healthcare provider to specialist’

and ‘symptom onset to first contact’. Both ‘diagnosis to specialist’ and ‘specialist to diagnosis’ paths were studied. Very few studies have researched onset of symptom to referral and specialist consultation. The time point ‘patient informed of diagnosis’ and intervals involving this time point were rarely studied.

Timeliness measures

The review identified 30 articles which conceptualised delay in the care pathway by adapting benchmarks from established guidelines to set cut-off values. The benchmarks were guided by British Thoracic Society (BTS) recommendations on organising the care of patients with lung cancer,⁴⁴ National Institute for Clinical Excellence (NICE) guideline,^{45 46} UK National Cancer Plan (UKNCP),⁴⁷ UK National Health Service (UKNHS) guideline,^{48 49} UK Department of Health guideline,⁵⁰ Research and Development (RAND) Corporation guideline,⁵¹ Canadian Strategy for Cancer Control,⁵² Canadian guidelines,⁵³ Standing Medical Advisory Committee (SMAC),⁵⁴ Cancer Council Australia and Cancer Australia,⁵⁵ Danish Lung Cancer Group and Registry,⁵⁶ Swedish Lung Cancer Group⁵⁷ and Scottish Executive Health Department (SEHD),^{58 59} Institute of Medicine,⁶⁰ Dutch Association of Physicians for Pulmonary Disease and Tuberculosis,⁶¹ Joint Council for Clinical Radiology,⁶² American College of Chest Physicians,⁶³ and Norwegian National Guidelines.⁶⁴

Six articles referenced cut-off values from other articles to compare timeliness^{24 35 41 65–67} and one article proposed a benchmark cut-off value based on their findings.⁶⁸ Fifteen articles used single guidelines and fifteen articles used more than one guideline to conceptualise timeliness measures. Out of 30 articles, BTS was adopted by 14 articles,^{23 25 27 28 33 41 65 69–75} UKNHS was used seven times,^{33 67 72 76–79} NICE guideline by four articles,^{71 73 80 81} RAND corporation guideline by four articles,^{33 70 75 82} and Canadian guidelines by four articles,^{27 28 41 83} SEHD guidelines by three articles,^{33 80 84} Danish Lung Cancer Group guidelines by three articles,^{33 67 85} UKNCP guidelines by two articles,^{71 86} SMAC guideline by two articles,^{33 84}

Table 4 Time intervals commonly studied—dark blue >10 (most commonly), light blue >7 (commonly), lighter blue >3 (occasionally), white=none

Starting point	Ending point					
	First contact with healthcare provider	Referral	Specialist consultation	Diagnosis	Patient informed of diagnosis	Initiation of treatment
Onset of symptom	18	3	3	9	-	11
First contact with healthcare provider	X	-	22	12	-	9
Referral		X	-	7	-	12
Specialist consultation			X	7	-	14
Diagnosis			4	X	3	28
Patient informed of diagnosis					X	3

Norwegian National Guidelines by two articles^{25 87} and Swedish Lung Cancer Group guidelines by two articles.^{28 33} Online supplemental file 3 describes the ‘measures of timeliness’/‘benchmark for intervals’ with cut-off values adopted from different guidelines. Table 5 presents the timeliness measures according to study settings.

BTS guidelines were those most frequently cited in the included studies (20%). Studies guided by the BTS guidelines adapted the definition of intervals and measurement of timeliness depending on the interval of interest. Common timeliness measures adapted from BTS included the length of time that should elapse from initial GP referral of suspected lung cancer to evaluation/respiratory assessment (≤ 1 week), primary care referral to receiving diagnostic tests (bronchoscopy/histology/cytology) (≤ 2 weeks), presentation of symptom to diagnosis (≤ 8 weeks), diagnosis to initiation of treatment (≤ 6 weeks), GP referral to specialist consultation (≤ 1 week), GP referral and initiation of any type of treatment (≤ 62 days), specialist consultation and surgery (thoracotomy) (≤ 8 weeks), surgical waiting list and thoracotomy (4 weeks), referral to surgeons (≤ 4 weeks), oncology referral to commencement of radiotherapy or chemotherapy (≤ 2 weeks), decision-to-treat to initiation of treatment (31 days).

Table 6 presents the frequently used intervals and guidelines to measure timeliness in the included articles.

Differences between Asian and Western countries

There were nine studies from five Asian countries/territories included in the scoping review. There were no differences in the terminology for labelling time points and intervals in the lung cancer care pathway between studies from Asian and Western countries. Studies from Asian countries/territories adapted timeline for intervals from Western guidelines in many instances. One study from India⁴¹ and several Turkish^{27 28 69} studies measured timeliness by adapting guidelines from the BTS, Canada and Sweden. The reporting of timeliness was not described as being guided by any specific guideline in studies from mainland China,⁴¹ Nepal,²⁶ Taiwan³⁴ and two other studies from India.^{88 89}

DISCUSSION

The lung cancer care journey is not linear. Eight time points found to be most frequently used time points in the included studies, which leads to variations in selection of time points and measurements of intervals (determined by the context) in different studies. Which introduces challenges in assessing timeliness due to lack of appropriate benchmarking, in particular in Asian countries. Moreover, different time points and intervals were defined, and different guidelines were used depending on the interest of the study objectives. This also makes comparisons across studies difficult.

Time points

Different time points were studied depending on the objective of the research in the included studies. ‘Onset

Table 5 Most frequently cited guidelines used to measure timeliness across settings

Guidelines	Articles included	Settings
1. British Thoracic Society	Lee <i>et al</i> UK ⁷⁴	UK
	Forrest <i>et al</i> UK ⁷⁸	
	Singh <i>et al</i> USA ⁶⁵ Schultz <i>et al</i> USA ⁷⁰	North America
	Olsson <i>et al</i> USA ¹⁰⁴	
	Ost <i>et al</i> USA ⁷⁵	
	Brocken <i>et al</i> Netherlands ²³ Rolke <i>et al</i> Norway ²⁵	Europe
	Malalasekera <i>et al</i> Australia ³³ Sood <i>et al</i> New Zealand ⁷³	Australia and New Zealand
	Özlü <i>et al</i> Turkey ⁶⁹ Yilmaz <i>et al</i> Turkey ²⁷	Asia
2. UK National Health Service	Sulu <i>et al</i> Turkey ²⁸	
	Chandra <i>et al</i> Indian ⁴¹	
	Barrett and Hamilton 2008 UK ¹⁰³	UK
	Huetto Pérez De Heredia <i>et al</i> Spain ⁷²	Europe
	Malalasekera <i>et al</i> Australia ³³ Alexander <i>et al</i> Australia ⁷⁶	Australia and New Zealand
	Evans <i>et al</i> Australia ⁷⁷ Sood <i>et al</i> New Zealand ⁷³ Largey <i>et al</i> Australia ⁶⁷	
3. National Institute for Clinical Excellence guideline	Baughan <i>et al</i> UK ⁸⁰ Forrest <i>et al</i> UK ⁷⁸	UK
	Olsson <i>et al</i> USA ¹⁰⁴	North America
	Verma <i>et al</i> Australia ¹⁰²	Australia and New Zealand
4. RAND corporation	Schultz <i>et al</i> USA ⁷⁰ Ost <i>et al</i> USA ⁷⁵ Bullard <i>et al</i> USA ⁸²	North America
	Malalasekera <i>et al</i> Australia ³³	Australia and New Zealand
5. Canadian guidelines	Grunfeld <i>et al</i> Canada ⁸³	North America
	Yilmaz <i>et al</i> Turkey ²⁷ Sulu <i>et al</i> Turkey ²⁸ Chandra <i>et al</i> India ⁴¹	Asia
6. Scottish Executive Health Department	Baughan <i>et al</i> UK ⁸⁰ Melling <i>et al</i> UK ⁸⁴	UK
	Malalasekera <i>et al</i> Australia ³³	Australia and New Zealand
7. Danish Lung Cancer Group	Iachina <i>et al</i> Denmark ⁸⁵	Europe
	Malalasekera <i>et al</i> Australia ³³ Largey <i>et al</i> Australia ⁶⁷	Australia and New Zealand
8. UK National Cancer Plan	Forrest <i>et al</i> UK ⁷⁸ Devbhandari <i>et al</i> UK ⁸⁶	UK
9. Standing Medical Advisory Committee	Melling <i>et al</i> UK ⁸⁴	UK
	Malalasekera <i>et al</i> Australia ³³	Australia and New Zealand
10. Norwegian National Guidelines	Stokstad <i>et al</i> Norway ⁸⁷ Rolke <i>et al</i> Norway ²⁵	Europe
11. Swedish Lung Cancer Group	Malalasekera <i>et al</i> Australia ³³	Australia and New Zealand
	Sulu <i>et al</i> Turkey ²⁸	Asia

Continued

Table 5 Continued

Guidelines	Articles included	Settings
12. Cut-off values referenced from other articles	Singh <i>et al</i> USA ⁶⁵	North America
	Shugarman <i>et al</i> USA ⁶⁶	
	Kanarek <i>et al</i> USA ³⁵	
	Koyi <i>et al</i> Sweden ²⁴	Europe
	Largey <i>et al</i> Australia ⁶⁷	Australia and New Zealand
	Chandra <i>et al</i> India ⁴¹	Asia

RAND, Research and Development.

of symptoms', 'first contact with a healthcare provider', 'specialist consultation', 'diagnosis' and 'initiation of treatment' were the most frequently studied time points. The first event in any health-seeking behaviour relates to the first health changes or the onset of symptom(s). It is difficult to capture the exact time point of onset of symptom(s) except by asking respondents directly. It may also be difficult to establish a link between onset of symptoms and health-seeking behaviour relating to the diagnosis of lung cancer as similar symptoms are shared by other respiratory diseases. Included studies obtained data from a variety of sources including cancer registries, longitudinal surveillance data, insurance claims data, and hospital records. Not all the studies included the time point 'onset of symptoms' because of the differences in the interval of interest or objective of the study. The relevance and importance of the first time point to understanding the overall patient care pathway is likely to vary across countries with different health systems and resources. In contrast, clinical processes post diagnosis are highly standardised. As a result, research about timeliness in healthcare is focused primarily on the time points prior to diagnosis.

After onset of symptom(s) the next time point in the care seeking pathway is first contact with any healthcare provider. The studies included in this review reported only contact with formal healthcare providers. This may have been because of the difficulty involved in capturing reliable information on seeking healthcare from informal healthcare providers in the absence of any specific record management system and because of the potential for recall bias associated with self-report. Nonetheless, informal healthcare providers (including provision of over-the-counter medicines from unregulated pharmacies, village doctors and traditional or herbal remedies) are predominant in developing countries where, sometimes, informal healthcare is the only available healthcare option accessible.⁹⁰ It was evident from the included studies that patients' movement across different tiers of the health system is dynamic and complex. These different tiers within the systems are often not interlinked and using different medical record systems. However, the studies do not necessarily interpret or present this information in a way that makes it easy to understand why the time points are not consistently recorded.

After first contact with any healthcare provider the next time point in the lung cancer care pathway is diagnosis or referral to the next level of healthcare for evaluation of the disease. The way this occurs will depend on the characteristics of the healthcare system and patient behaviour. In some settings, there may be multiple contacts with different providers and the diagnosis could be made at any point, not just as an 'endpoint' before hospital admission. Furthermore, the way patients move across different sectors and services will vary across health systems but may not be described clearly in studies. Patients do not necessarily move through time points in sequential order. In some systems, patients may bypass certain time points. Most included studies were conducted in countries with a 'gate keeper' system consisting of GPs as the first point of contact for healthcare. However, this pathway is not common to all healthcare systems, and was generally not seen in studies from Asian countries. In these countries, confirmatory investigation requisition can be initiated before the referral to a specialist. For instance, a request for a CT and fine needle aspiration cytology can be initiated by a primary care physician and hence, a patient can be diagnosed with lung cancer by a GP before referral to secondary healthcare. Some of the studies included a time point reflecting hospital admission or first specialist visit date. Inclusion of referral time and hospital admission time or first specialist consultation time helped to measure the time elapsed from date of referral to consultation with a specialist or hospital admission. The date when a patient was informed of his/her diagnosis was mentioned by three studies. The last time point in the disease care pathway is the date of initiation of any oncological treatment.

Intervals

Studies have segmented the lung cancer care pathway into different intervals depending on the objectives of those studies and sources of data. 'Onset of symptom' to 'first contact with any healthcare provider', 'first contact with any healthcare provider to 'specialist consultation', 'first contact with any healthcare provider to 'diagnosis' and 'diagnosis' to 'initiation of treatment' were the most commonly used intervals in the included articles. However, there were marked differences in how the intervals were named and this heterogeneity in typologies can be misleading as the same name is used for different intervals. For instance, the 'patient's application interval' and 'the time between onset of symptoms to first contact with primary healthcare provider' were descriptions of the same interval in two studies^{27 28} while the term 'patient delay' was used to measure both 'onset of symptom to primary healthcare provider'²¹⁻²⁶ and 'onset of symptom to secondary healthcare provider'³⁶ intervals. 'Patient delay' may not be entirely related to patient factors as lack of health resources can influence the time lapse from onset of symptom to contact with a healthcare provider.

Similarly, the interval 'first contact with a primary healthcare provider to secondary healthcare provider'

Table 6 Guidelines and interval benchmarks referenced in included articles

	BTS	NICE	UKNCP	UKNHS	UKDoH	RAND	CSCC	SMAC	SEHD	SIGN	NOLCP	CCA	SLCG	DLCG	DAP PDT	NNG	ACCP	IOM
Onset of symptoms to first doctor visit	■																	
First clinical presentation to first suspicious investigation														■				
First abnormal investigation (Chest X-Ray) to confirmation of diagnosis/ specialist visit	■					■												
GP to Specialist	■	■		■	■	■	■	■	■	■		■	■	■	■	■	■	■
Primary care to initiation of treatment	■		■	■	■	■	■	■					■	■		■		
Referral to secondary care to diagnosis	■			■	■		■							■				
First referral to secondary care to treatment start	■	■		■	■			■	■		■	■		■				
First clinical presentation to Diagnosis					■	■												
First investigation to treatment														■				
Diagnostic investigation to patient informed of diagnosis	■																	
Diagnosis to Treatment start				■	■	■	■				■	■	■	■	■			
First clinical presentation to treatment start				■				■		■								
Decision to treatment to initiation of treatment	■		■															
Surgery to chemotherapy (Adjuvant chemotherapy)				■			■											
Referral receipt to specialist consultation		■		■				■	■									
Oncology referral to radiotherapy/ chemotherapy	■	■																
Specialist consultation to surgery	■	■	■															
Surgeon consultation/ Surgical waiting list to surgery	■	■																
Onset of symptoms to treatment	■				■													

Continued

Table 6 Continued

	BTS	NICE	UKNCP	UKNHS	UKDoH	RAND	CSCC	SMAC	SEHD	SIGN	NOLCP	CCA	SLCG	DLCG	DAPDPT	NNG	ACCP	IOM
Primary care referral to first diagnostic evaluation of symptom	■																	
Primary care referral to completion of evaluation at referral centre	■																	

ACCP, American College of Chest Physicians; BTS, British Thoracic Society; CCA, Cancer Council Australia; CSCC, Canadian Strategy for Cancer Control; DAPDPT, Dutch Association of Physicians for Pulmonary Disease and Tuberculosis; DLCG, Danish Lung Cancer Group; GP, general practitioner; IOM, Institute of Medicine; NHMRC, National Health and Medical Research Council; NICE, National Institute for Health and Care Excellence; NNG, Norwegian National Guidelines; NOLCP, National Optimal Lung Cancer Pathway; RAND, Research and Development USA; SEHD, Scottish Executive Health Department; SIGN, Scottish Intercollegiate Guideline Network; SLCG, Swedish Lung Cancer Group; SMAC, Standing Medical Advisory Committee; UKDoH, UK Department of Health; UKNCP, UK National Cancer Plan; UKNHS, UK National Health Service.

was measured to reflect ‘referral delay’^{21 23 25} in some studies³⁵ and ‘diagnosis to secondary/tertiary healthcare provider’ and ‘referral or receipt of referral by a specialist to diagnosis’³⁰ in others. There were also differences in defining diagnostic intervals including ‘from first contact with the secondary healthcare provider to diagnosis’,^{28 31} ‘from first contact with primary healthcare provider to diagnosis’,^{29 30 32–34} and ‘from onset of symptom to diagnosis’.^{29 38} The interval between ‘first contact with primary healthcare provider’ and ‘treatment initiation’ was labelled as ‘system delay’²² and ‘system interval’ and was also described as the ‘diagnosis to initiation of treatment’ interval.⁴⁰ ‘Treatment delay’ was measured using the intervals ‘diagnosis to initiation of treatment’,²² and ‘onset of symptoms to initiation of treatment’.⁴¹ Use of different terminology for the same intervals and use of the same terminology to label different intervals is confusing and can lead to difficulties in interpreting results. Standardised typology would be helpful in order to streamline consistency and enable comparability across studies.

Timeliness

The terms ‘delay’ and ‘interval’ were both used in studies to describe timeliness. The term ‘delay’ conveys a negative connotation, despite most articles using the term in the absence of benchmarking. It would seem more appropriate to use the term ‘time interval’ rather than ‘delay’ as this may imply, inaccurately, that the patient has not sought help promptly. Therefore, several articles suggested using the term ‘time interval’ as a neutral alternative to ‘delay’.^{11 12 91} In contrast, other researchers have argued that the term ‘time interval’ should not be replaced by ‘delay’ unless the results are compared with others or against benchmarks.

There are some differences in the recommended timeframes for each interval between the guidelines. There were similarities in timeliness measures between the BTS guidelines and most of the European guidelines, with some differences compared with the North American guidelines.

More than half of the included studies (38) did not quantify upper limits for intervals based on existing guidelines. Studies which did not compare their results to any guideline generally compared their results with other timeliness of lung cancer treatment related studies and among the subgroups of patients within the study. Studies also have used different time intervals with different time points. As a result, they were not always comparable between studies. The comparison and interpretation of the results were difficult and created confusion when the studies were not from similar context and health system strength.

Asian and Western country differences

There were no differences between Asian and Western countries in the way they defined timeliness of care. Among 68 studies included in this review, nine studies were from Asian countries and/or territories.^{22 26–28 34 41 69 88 89} Four

of nine Asian studies used Western lung cancer guidelines to measure timeliness^{27 28 41 69} and the other five studies did not use a guideline. It remains unclear how effective and relevant Western guidelines are for Asian countries, especially those with low and middle income. The lack of qualified providers, low availability of surgery and radiotherapy services, and poor access to and affordability of up-to-date treatments remain a prevailing concern for lung cancer care in low-income and middle-income countries (LMICs) compared with high-income countries (HICs).^{8 9} Moreover, universal healthcare and health insurance mechanisms are still in the development phase in many Asian countries and LMICs. Western guidelines were developed in a context where such health system factors contribute to the effectiveness of guidelines. Using a guideline meant for highly resourced health systems in a resource-constrained country may not accurately reflect expectations and goals for timeliness of lung cancer care; culturally sensitive and resource-sensitive guidelines are likely required.⁸ As most of the existing guidelines do not account for diversity in health resources, economic disparities or healthcare infrastructure, their applicability could be limited.^{92 93} The articles included from Asian countries/territories did not discuss the compatibility of Western guidelines in terms of relevance and appropriateness of recommended time limits for intervals in the disease care pathway in their context. Although the use of Western guidelines for LMICs with different health systems may not be appropriate, there is currently no guideline for lung cancer care which dictates standard time limits that considers the limitations of weaker health systems. The Asian Oncology Summit 2009 proposed a resource-stratified management guideline for non-small cell lung cancer treatment; however, it does not provide benchmarking for intervals in the care pathway, which need to be developed by respective countries adapting this guideline.¹⁰ Informal healthcare is a unique feature of the diverse healthcare system in Asian countries and LMICs, whereas Western guidelines do not have to consider the inclusion of informal healthcare in the care pathway for lung cancer. Considering inclusion of a time point related to informal healthcare seeking and a measure of the number of times patients sought care from informal healthcare providers could be useful for Asian countries and LMIC settings.

This scoping review is not devoid of limitations. The broad search strategy enabled inclusion of different study designs. This scoping review used a robust and established method guided by a published protocol. Independent screening and assessment of articles against inclusion and exclusion criteria by authors ensured minimisation of selection bias. As this review followed a scoping review methodology, it did not assess the quality of the included articles. Excluding Arksey and O'Malley's optional stage of conducting stakeholder consultation might have limited this scoping review from reaching a consensus, however, the authors intended to undertake stakeholder consultation in the next phase of the research project based on the availability of funding. The majority of

the included studies were from HICs, thus limiting the generalisability for low-income countries. Only studies published in English were included in the review, which could have missed potentially relevant literature in other languages. The search strategy used the most widely used databases; however, articles which were not identified through those databases could have been missed. Although we used common search terms for our search, missing a pertinent term could have limited the search results. Other potential limitations were limiting the search and inclusion of articles published in the last 20 years.

CONCLUSION

Although this review identified similarities in most of the time points and intervals of the included studies, there were substantial variations in selection and interpretation of the meaning of intervals. This lack of consistency creates a challenge for researchers who are trying to undertake research about timeliness of care for lung cancer. As timeliness of care studies are mostly carried out in Western countries and guidelines appear unsuited to weaker healthcare delivery systems, there is a need to revisit existing definitions to conduct timeliness of care related studies and a unified set of definitions needs to be set which can accommodate different structures and characteristics of health systems. The differences in healthcare delivery systems of Asian and Western countries, and between HICs and LMICs may suggest different sets of time points and intervals that reflect resources and feasibility need to be developed. The lack of data capture points in weaker resource-poor health systems and the presence of unregulated and untrained healthcare providers in LMICs make it difficult to conduct research on timeliness of lung cancer care. Differences in the structure and strength of health systems create challenges when comparing results of health service research in lung cancer between HICs and LMICs. Existing frameworks for understanding healthcare pathways such as The Aarhus Statement and Andersen's model of health service utilisation could support synthesis of research but would need to be revisited and modified to be applicable to LMIC-specific contexts.

Author affiliations

¹School of Nursing and Midwifery, College of Science Health and Engineering, La Trobe University, Melbourne, Victoria, Australia

²Institute for Breathing and Sleep (IBAS), Melbourne, Victoria, Australia

³Australian Institute for Primary Care and Aging, La Trobe University, Bundoora, Victoria, Australia

⁴Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia

⁵University of Melbourne, Melbourne, Victoria, Australia

⁶School of Psychology and Public Health, La Trobe University, Bundoora, Victoria, Australia

⁷School of Health, Federation University Australia, Berwick, Victoria, Australia

⁸Department of Noncommunicable Diseases, Bangladesh University of Health Sciences (BUHS), Dhaka, Bangladesh

⁹Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia

Acknowledgements The authors would like to acknowledge Saima Sultana, Lauren Zarb and Bijaya Pokharel for their collaboration and assistance with article screening for this review. We would like to thank the La Trobe University library for giving the access to the database for search.

Contributors AA is the guarantor and conceived the study, developed the protocol and search strategy, conducted the data charting, interpretation and manuscript development. AR and VL contributed to screening the articles, CL, CFM, AR and VL contributed to analysis, interpretation and critical feedback in manuscript finalisation. All authors provided critical comments and input to revisions to the paper and approved the final manuscript for submission.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Ethical approval is not needed as this scoping review reviewed already published articles.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Adnan Ansar <http://orcid.org/0000-0001-6052-8657>

Christine Faye McDonald <http://orcid.org/0000-0001-6481-3391>

Chaojie Liu <http://orcid.org/0000-0003-0877-0424>

REFERENCES

- Wild CP, Weiderpass E, Stewart BW, eds. *World Cancer Report: Cancer Research for Cancer Prevention*. Lyon, France: International Agency for Research on Cancer, WHO, 2020.
- Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncol* 2019;20:1493-505.
- Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* 2018;391:1023-75.
- Schabath MB, Cote ML. And priorities: lung cancer. *Cancer Epidemiol Biomarkers Prev* 2019;28:1563-79.
- Fisher DA, Zullig LL, Grambow SC, et al. Determinants of medical system delay in the diagnosis of colorectal cancer within the veteran Affairs health system. *Dig Dis Sci* 2010;55:1434-41.
- Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. *Br J Cancer* 2012;106:1262-7.
- Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. *Clin Respir J* 2016;10:267-71.
- Anderson BO. Evidence-Based methods to address disparities in global cancer control: the development of guidelines in Asia. *Lancet Oncol* 2013;14:1154-5.
- Edelman Saul E, Guerra RB, Edelman Saul M, et al. The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries. *Nat Cancer* 2020;1:1140-52.
- Soo RA, Anderson BO, Cho BC, et al. First-Line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian oncology Summit 2009. *Lancet Oncol* 2009;10:1102-10.
- Walter F, Webster A, Scott S, et al. The Andersen model of total patient delay: a systematic review of its application in cancer diagnosis. *J Health Serv Res Policy* 2012;17:110-8.
- Scott SE, Walter FM, Webster A, et al. The model of pathways to treatment: conceptualization and integration with existing theory. *Br J Health Psychol* 2013;18:45-65.
- Coxon D, Campbell C, Walter FM, et al. The Aarhus statement on cancer diagnostic research: turning recommendations into new survey instruments. *BMC Health Serv Res* 2018;18:677.
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19-32.
- Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci* 2010;5:69.
- Peters MDJ, Godfrey C, McInerney P. Chapter 11: Scoping Reviews. In: Aromataris E ZM, ed. *Joanna Briggs Institute Reviewer's Manual*. The Joanna Briggs Institute, 2017.
- Centre for Reviews and Dissemination, University of York. Systematic Reviews CRD's guidance for undertaking reviews in health care York YO31 7ZQ: University of York, 2009. Available: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf [Accessed 2 Nov 2020].
- Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467-73.
- Ansar A, Lewis V, McDonald CF, et al. Defining timeliness in care for patients with lung cancer: protocol for a scoping review. *BMJ Open* 2020;10:e039660.
- Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol* 2014;67:1291-4.
- Salomaa E-R, Sällinen S, Hiekkänen H, et al. Delays in the diagnosis and treatment of lung cancer. *Chest* 2005;128:2282-8.
- Yang DW, Zhang Y, Hong QY. Determination of time to diagnosis for lung cancer patients and the role of a serum based biomarker panel in the early diagnosis for cohort of highrisk, symptomatic patients. *Cancer* 2015;121:3113-21.
- Brocken P, Kiers BAB, Looijen-Salamon MG, et al. Timeliness of lung cancer diagnosis and treatment in a rapid outpatient diagnostic program with combined 18FDG-PET and contrast enhanced CT scanning. *Lung Cancer* 2012;75:336-41.
- Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest tumors. *Lung Cancer* 2002;35:53-7.
- Rolke HB, Bakke PS, Gallefoss F. Delays in the diagnostic pathways for primary pulmonary carcinoma in southern Norway. *Respir Med* 2007;101:1251-7.
- Thapa B, Sayami P. Low lung cancer resection rates in a tertiary level thoracic center in Nepal--where lies our problem? *Asian Pac J Cancer Prev* 2014;15:175-8.
- Yilmaz A, Damadoglu E, Salturk C, et al. Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage? *Ups J Med Sci* 2008;113:287-96.
- Sulu E, Tasolar O, Berk Takir H, et al. Delays in the diagnosis and treatment of non-small-cell lung cancer. *Tumori* 2011;97:693-7.
- Emery JD, Walter FM, Gray V, et al. Diagnosing cancer in the bush: a mixed methods study of GP and specialist diagnostic intervals in rural Western Australia. *Fam Pract* 2013;30:541-50.
- Helsper CCW, van Erp NNF, Peeters PPHM, et al. Time to diagnosis and treatment for cancer patients in the Netherlands: room for improvement? *Eur J Cancer* 2017;87:113-21.
- Gonzalez-Barcala FJ, Falagan JA, Garcia-Prim JM, et al. Timeliness of care and prognosis in patients with lung cancer. *Ir J Med Sci* 2014;183:383-90.
- Rankin NM, York S, Stone E, et al. Pathways to lung cancer diagnosis: a qualitative study of patients and general practitioners about diagnostic and pretreatment intervals. *Ann Am Thorac Soc* 2017;14:742-53.
- Malalasekera A, Nahm S, Blinman PL. How long is too long? A scoping review of health system delays in lung cancer. *European Respiratory Review* 2018;27:30.
- Hsieh VC-R, Wu T-N, Liu S-H, et al. Referral-free health care and delay in diagnosis for lung cancer patients. *Jpn J Clin Oncol* 2012;42:934-9.

- 35 Kanarek NF, Hooker CM, Mathieu L, *et al.* Survival after community diagnosis of early-stage non-small cell lung cancer. *Am J Med* 2014;127:443–9.
- 36 Ampil FL, Caldito G. Patient-Provider delays in superior vena caval obstruction of lung cancer and outcomes. *Am J Hosp Palliat Care* 2014;31:441–3.
- 37 Bucchieri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. *Eur Respir J* 2004;24:898–904.
- 38 Walter FM, Rubin G, Bankhead C. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. *British Journal of Cancer* 2015;03.
- 39 Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. *Lung Cancer* 2001;34:243–52.
- 40 Kim JOA, Davis F, Butts C, *et al.* Waiting time intervals for non-small cell lung cancer diagnosis and treatment in Alberta: quantification of intervals and identification of risk factors associated with delays. *Clin Oncol* 2016;28:750–9.
- 41 Chandra S, Mohan A, Guleria R, *et al.* Delays during the diagnostic evaluation and treatment of lung cancer. *Asian Pac J Cancer Prev* 2009;10:453–6.
- 42 Maiga AW, Deppen SA, Pinkerman R. Timeliness of care and lung cancer Tumor-Stage progression: how long can we wait? *Annals of Thoracic Surgery* 2017;104:1791–7.
- 43 Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. *J Thorac Dis* 2011;3:183–8.
- 44 Bts recommendations to respiratory physicians for organising the care of patients with lung cancer. the lung cancer Working Party of the British thoracic Society standards of care Committee. *Thorax* 1998;53 Suppl 1:S1–8.
- 45 National Institute for Health and Clinical Excellence. *Referral guidelines for suspected cancer*. London: NICE, 2005.
- 46 NICE. *Lung cancer: diagnosis and management CG121 National Institute for health care excellence* 2011, 2011.
- 47 Executive N. *The National cancer plan: a plan for investment, a plan for reform*. London: Department of Health, 2000.
- 48 National Health Service (NHS). *The operating framework for the NHS in England 2012/13*. Produced by COI on behalf of the Department of Health.
- 49 England N. *Everyone counts: planning for patients 2014/15 to 2018/19*. England: NHS, 2013.
- 50 Department of Health. *Referral guidelines for suspected cancer – consultation document November 1999*. United Kingdom Department of Health. 1999, 1999.
- 51 Asch SM, Kerr EA, Hamilton EG. Quality of care for oncologic conditions and HIV: a review of the literature and quality indicators: Rand CORP SANTA MONICA Ca 2000.
- 52 Control. CSfC. *The Canadian strategy for cancer control: a cancer plan for Canada*. Canadian Strategy for Cancer Control Governing Council, 2006.
- 53 Simunovic M, Gagliardi A, McCreedy D, *et al.* A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. *CMAJ* 2001;165:421–5.
- 54 Whitehouse, JMA. *Management of lung cancer current clinical practices*. London: Standing Medical Advisory Committee, 1994.
- 55 Cancer Council Australia and cancer Australia (Australian government). optimal care pathway for people with lung cancer. *Australia* 2016.
- 56 Jakobsen E, Green A, Oesterlind K, *et al.* Nationwide quality improvement in lung cancer care: the role of the Danish lung cancer group and registry. *J Thorac Oncol* 2013;8:1238–47.
- 57 Hillerdal G. Recommendations from the Swedish lung cancer Study group: shorter waiting times are demanded for quality in diagnostic work-ups for lung care. *Swedish Med J* 1999;96:4691.
- 58 Scottish Executive Health Department. *Cancer in Scotland: action for change*. Edinburgh: SEHD, 2001.
- 59 Scottish Executive Health Department. *Scottish referral guidelines for suspected cancer*. 2007. Edinburgh: SEHD, 2007.
- 60 Kaplan G, Lopez MH, McGinnis JM. *Transforming health care scheduling and access: getting to now*. Washington, DC: Institute of Medicine (IOM), 2015.
- 61 Dutch Association of Physicians for Pulmonary Disease and Tuberculosis. *Non-Small cell lung cancer guideline: staging and treatment*, 2004.
- 62 Oncology Jcfc. Improving quality of cancer care: reducing delays in cancer treatment. *Clinical oncology (Royal College of Radiologists)* 1993.
- 63 Alberts W, Beppler G, Hazelton T. American College of chest physicians. *Chest* 2003;123:332S–7.
- 64 The Norwegian directorate of health. *Norwegian national guidelines for lung cancer management*, 2014.
- 65 Singh H, Hirani K, Kadiyala H, *et al.* Characteristics and predictors of missed opportunities in lung cancer diagnosis: an electronic health record-based study. *J Clin Oncol* 2010;28:3307–15.
- 66 Shugarman LR, Mack K, Sorbero MES, *et al.* Race and sex differences in the receipt of timely and appropriate lung cancer treatment. *Med Care* 2009;47:774–81.
- 67 Largey G, Ristevski E, Chambers H, *et al.* Lung cancer interval times from point of referral to the acute health sector to the start of first treatment. *Aust Health Rev* 2016;40:649–54.
- 68 Vidaver RM, Shershneva MB, Hetzel SJ, *et al.* Typical time to treatment of patients with lung cancer in a multisite, US-Based study. *J Oncol Pract* 2016;12:e643–53.
- 69 Ozlü T, Bülbül Y, Oztuna F, *et al.* Time course from first symptom to the treatment of lung cancer in the eastern black sea region of turkey. *Med Princ Pract* 2004;13:211–4.
- 70 Schultz EM, Powell AA, McMillan A, *et al.* Hospital characteristics associated with timeliness of care in veterans with lung cancer. *Am J Respir Crit Care Med* 2009;179:595–600.
- 71 Devbhandari MP, Bittar MN, Quennell P, *et al.* Are we achieving the current waiting time targets in lung cancer treatment? result of a prospective study from a large United Kingdom teaching hospital. *J Thorac Oncol* 2007;2:590–2.
- 72 Evaluation of the use of a rapid diagnostic consultation of lung cancer. *Arch Bronconeumol* 2012;48:267–73.
- 73 Sood J-deep, Wong C, Bevan R, *et al.* Delays in the assessment and management of primary lung cancers in South Auckland. *N Z Med J* 2009;122:42–50.
- 74 Lee J, Marchbank A, Goldstraw P. Implementation of the British thoracic Society recommendations for organising the care of patients with lung cancer: the surgeon's perspective. *Ann R Coll Surg Engl* 2002;84:304–8.
- 75 Ost DE, Jim Yeung S-C, Tanoue LT, *et al.* Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ED: American College of chest physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e121S–41.
- 76 Alexander M, Beattie-Manning R, Blum R, *et al.* Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services. *Intern Med J* 2016;46:964–9.
- 77 Evans SM, Earnest A, Bower W, *et al.* Timeliness of lung cancer care in Victoria: a retrospective cohort study. *Med J Aust* 2016;204:75.
- 78 Forrest LF, Adams J, White M, *et al.* Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: population-based, data-linkage study. *Br J Cancer* 2014;111:1843–51.
- 79 Di Girolamo C, Walters S, Gildea C, *et al.* Can we assess cancer waiting time targets with cancer survival? a population-based study of individually linked data from the National cancer waiting times monitoring dataset in England, 2009–2013. *PLoS One* 2018;13:e0201288.
- 80 Baughan P, O'Neill B, Fletcher E. Auditing the diagnosis of cancer in primary care: the experience in Scotland. *Br J Cancer* 2009;101:S87–91.
- 81 Ezer N, Navasakulpong A, Schwartzman K, *et al.* Impact of rapid investigation clinic on timeliness of lung cancer diagnosis and treatment. *BMC Pulm Med* 2017;17:178.
- 82 Bullard JT, Eberth JM, Arrington AK, *et al.* Timeliness of treatment initiation and associated survival following diagnosis of non-small-cell lung cancer in South Carolina. *South Med J* 2017;110:107–13.
- 83 Grunfeld E, Watters JM, Urquhart R, *et al.* A prospective study of peri-diagnostic and surgical wait times for patients with presumptive colorectal, lung, or prostate cancer. *Br J Cancer* 2009;100:56–62.
- 84 Melling PP, Hatfield AC, Muers MF, *et al.* Lung cancer referral patterns in the former Yorkshire region of the UK. *Br J Cancer* 2002;86:36–42.
- 85 Iachina M, Jakobsen E, Fallesen AK, *et al.* Transfer between hospitals as a predictor of delay in diagnosis and treatment of patients with Non-Small Cell Lung Cancer - a register based cohort-study. *BMC Health Serv Res* 2017;17:267.
- 86 Devbhandari MP, Quennell P, Krysiak P, *et al.* Implications of a negative bronchoscopy on waiting times to treatment for lung cancer patients: results of a prospective tracking study. *Eur J Cardiothorac Surg* 2008;34:479–83.
- 87 Stokstad T, Sørhaug S, Amundsen T, *et al.* Medical complexity and time to lung cancer treatment - a three-year retrospective chart review. *BMC Health Serv Res* 2017;17:45.

- 88 Sachdeva R, Sachdeva S. Delay in diagnosis amongst carcinoma lung patients presenting at a tertiary respiratory centre. *Clinical Cancer Investigation Journal* 2014;3:288–92.
- 89 Dubey N, Arti J, Varudkar H. A clinico-pathological profile of primary lung cancer patients presenting in a rural medical College of central India. *Panacea Journal of Medical Sciences* 2016;5:124–9.
- 90 Sudhinaraset M, Ingram M, Lofthouse HK, *et al.* What is the role of informal healthcare providers in developing countries? A systematic review. *PLoS One* 2013;8:e54978.
- 91 De Nooijer J, Lechner L, De Vries H. Help-Seeking behaviour for cancer symptoms: perceptions of patients and general practitioners. *Psychooncology* 2001;10:469–78.
- 92 Tan D, Lee JH, Chen W, *et al.* Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. consensus statement of the Asian myeloma network at the 16th international myeloma workshop. *Leuk Lymphoma* 2018;59:2305–17.
- 93 Williams S, Chiong E, Lojanapiwat B, *et al.* Management of prostate cancer in Asia: resource-stratified guidelines from the Asian oncology Summit 2013. *Lancet Oncol* 2013;14:e524–34.
- 94 Corner J, Hopkinson J, Fitzsimmons D, *et al.* Is late diagnosis of lung cancer inevitable? interview study of patients' recollections of symptoms before diagnosis. *Thorax* 2005;60:314–9.
- 95 Dobson C, Russell A, Brown S, *et al.* The role of social context in symptom appraisal and help-seeking among people with lung or colorectal symptoms: a qualitative interview study. *Eur J Cancer Care* 2018;27:e12815.
- 96 Neal RD, Robbè LJ, Lewis M, *et al.* The complexity and difficulty of diagnosing lung cancer: findings from a national primary-care study in Wales. *Prim Health Care Res Dev* 2015;16:436–49.
- 97 Smith SM, Campbell NC, MacLeod U, *et al.* Factors contributing to the time taken to consult with symptoms of lung cancer: a cross-sectional study. *Thorax* 2009;64:523–31.
- 98 Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. *J Hematol Oncol* 2019;12:47.
- 99 Largey G, Chakraborty S, Tobias T, *et al.* Audit of referral pathways in the diagnosis of lung cancer: a pilot study. *Aust J Prim Health* 2015;21:106–10.
- 100 Li X, Scarfe A, King K, *et al.* Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer. *Int J Qual Health Care* 2013;25:197–204.
- 101 Sawicki M, Szczurek M, Krawczyk P, *et al.* Reasons for delay in diagnosis and treatment of lung cancer among patients in Lublin Voivodeship who were consulted in thoracic surgery department. *Ann Agric Environ Med* 2013;20:72–6.
- 102 Verma R, Pathmanathan S, Otty ZA, *et al.* Delays in lung cancer management pathways between rural and urban patients in North Queensland: a mixed methods study. *Intern Med J* 2018;48:1228–33.
- 103 Barrett J, Hamilton W. Pathways to the diagnosis of lung cancer in the UK: a cohort study. *BMC Fam Pract* 2008;9:31.
- 104 Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. *Thorax* 2009;64:749–56.
- 105 Wai ES, Mackinnon M, Hooker R, *et al.* Wait times in diagnostic evaluation and treatment for patients with stage III non-small cell lung cancer in British Columbia. *Am J Clin Oncol* 2012;35:373–7.
- 106 Winget M, Turner D, Tonita J, *et al.* Across-province standardization and comparative analysis of time-to-care intervals for cancer. *BMC Cancer* 2007;7:186.
- 107 Zullig LL. Equity in an equal access system? - quality & timeliness of cancer care in the veterans affairs healthcare system. *Dissertation Abstracts International: Section B: The Sciences and Engineering* 2014;74.
- 108 Bjerager M, Palshof T, Dahl R, *et al.* Delay in diagnosis of lung cancer in general practice. *Br J Gen Pract* 2006;56:863–8.
- 109 Hubert J, Bourdages-Pageau E, Garneau CAP, *et al.* Enhanced recovery pathways in thoracic surgery: the Quebec experience. *J Thorac Dis* 2018;10:S583–90.
- 110 Borrayo EA, Scott KL, Drennen AR, *et al.* Determinants of treatment delays among underserved Hispanics with lung and head and neck cancers. *Cancer Control* 2016;23:390–400.
- 111 Yorio JT, Xie Y, Yan J, *et al.* Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? *J Thorac Oncol* 2009;4:1322–30.

Search strategy for different database

Database	Search strategy
Medline	exp Lung Neoplasms/ OR exp Carcinoma, Non-Small-Cell Lung/ OR exp Carcinoma, Small Cell/ OR adenocarcinoma/ OR exp adenocarcinoma, bronchiolo-alveolar/ OR exp pulmonary adenomatosis, ovine/ AND General Practitioners/ OR Family Practice/ OR General Practice/ OR Primary Health Care/ OR Secondary healthcare.mp. OR Patient Admission/ OR exp Tertiary Healthcare/ OR Hospitals, Public/ OR Hospitals, Private/ OR Hospitals, Special/ OR Palliative Care/ OR exp Pulmonologists/ OR exp Oncologists/ OR exp surgical oncology/ OR exp thoracic surgery/ OR "Referral and Consultation"/ AND Diagnostic timelines.mp. OR Delay.mp. OR exp "Early Detection of Cancer"/ OR Primary delay.mp. OR Secondary delay.mp. OR Tertiary delay.mp. OR Health system delay.mp. OR Timeliness.mp. OR Interval.mp. OR Patient interval.mp. OR Patient delay.mp. OR Clinician delay.mp. OR Physician delay.mp. OR "Referral and Consultation"/ OR Referral delay.mp. OR exp *Delayed Diagnosis/ OR Diagnosis delay.mp. OR Diagnostic evaluation.mp. OR exp *Time-to-Treatment/ OR Treatment initiation.mp. OR Treatment initiation.mp. OR Treatment delay.mp OR exp *Waiting Lists/ OR Wait time.mp. OR exp "Appointments and Schedules"/ OR Wait time intervals.mp. OR Help seeking intervals.mp. OR *Prognosis/ OR Lung cancer Survival.mp. OR Prognostic implication.mp. AND limit 43 to (English language and humans and last 20 years)
Embase	exp lung tumor/ OR exp non-small cell lung cancer/ OR exp small cell lung cancer/ OR exp lung adenocarcinoma/ AND General Practitioners.mp. or exp general practitioner/ OR exp primary health care/ OR exp secondary health care/ OR exp tertiary health care/ OR exp public hospital/ OR exp private hospital/ OR exp cancer center/ OR exp palliative therapy/ OR exp pulmonologist/ OR exp thoracotomy/ OR exp lung lobectomy/ OR exp *patient referral/ OR exp consultation/ AND exp delayed diagnosis/ OR Primary delay.mp. OR Secondary delay.mp. OR tertiary delay.mp. OR health care system/ OR health care system delay.mp. OR timeliness.mp. OR Patient interval.mp. OR Patient delay.mp. OR Clinician delay.mp. OR Physician delay.mp. OR delayed lung cancer diagnosis.mp. OR time to diagnosis.mp. OR time to treatment.mp. or *time to treatment/ OR Treatment initiation.mp. OR treatment delay.mp. OR *hospital admission/ OR Help seeking intervals.mp. OR Lung cancer Survival.mp. OR lung cancer prognosis.mp. AND limit 41 to (human and English language and last 20 years)
PsycINFO	exp neoplasm/ OR (Lung Neoplasms or (lung adj3 neoplasm)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR (lung cancer or (lung adj3 cancer)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR Respiratory tract cancer.mp. OR Bronchogenic carcinoma.mp. OR Non-Small-Cell Lung Cancer.mp. OR Non-Small-Cell Lung Carcinoma.mp. OR Small Cell lung Cancer.mp. OR Small Cell lung Carcinoma.mp. OR (Lung cancer symptom* or (lung cancer adj3 symptom*)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] AND physicians/ or exp family physicians/ or exp general practitioners/ OR (General Practitioner* or General practice or Family Practice or Family Physician*).mp. OR (Primary healthcare or Secondary healthcare or Tertiary healthcare).mp. OR (Public hospital* or Private hospital* or Special hospital* or Cancer hospital* or Cancer Center* or cancer centre*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR exp palliative care/ OR Cancer Palliative care.mp. OR (Pulmonologist* or oncologist* or thoracic surger*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR (Thoracotomy* or Lung lobectomy* or Pneumonectomy*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR (Cancer surgical resection* or Surgical resection*).mp. OR (Referral or consultation).mp. OR ((Healthcare adj2 delivery) or patient admission).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] AND (Diagnostic timeline* or Timeliness).mp. OR (((early detection adj3 cancer) or delay* detection) adj5 cancer).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR (Primary delay* or

Database	Search strategy
	Secondary delay* or Tertiary delay* or Health system delay*).mp. OR (Patient interval* or Patient delay* or Clinician delay* or Physician delay*).mp. OR Referral delay*.mp. OR ((diagnos* adj3 delay*) or diagnostic evaluation).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR ((time adj3 treatment or treatment initiation).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR Treatment delay*.mp. OR (wait* time* or wait* time* interval or wait* list* or appointment).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] OR Health service accessibility.mp. OR Help seeking intervals.mp. OR (Prognostic implication* or Lung cancer Survival*).mp. AND limit 38 to (human and English language and last 20 years)
CINAHL	(MH "Respiratory Tract Neoplasms+") OR (MH "Lung Neoplasms+") OR (MH "Carcinoma, Non-Small-Cell Lung/DI/DT/EP/HI/MO/PR/RA/RT/RH/SU/SS/TH") OR (MH "Carcinoma, Small Cell/DI/DT/EP/HI/MO/PR/RA/RT/SU/SS/TH") OR "carcinoma, non-small-cell lung OR Carcinoma, Small Cell lung" OR "lung adenocarcinoma" AND (MH "Physicians, Family") OR (MH "Primary Health Care") OR (MH "Family Practice") OR "general practitioner or gp or family doctor or primary care" OR (MH "Secondary Health Care") OR (MH "Multidisciplinary Care Team") OR (MH "Tertiary Health Care") OR (MH "Hospitals, Public") OR (MH "Hospitals, Private") OR (MH "Hospitals, Veterans") OR (MH "Hospitals, Military") OR (MH "Hospitals, Special") OR (MH "Hospitals, Urban") OR (MH "Hospitals, Rural") OR (MH "Cancer Care Facilities") OR (MH "Oncologic Care+") OR (MH "Pulmonologists") OR (MH "Oncologists") OR "pulmonologist OR oncologist" OR (MH "Surgery, Lung+") OR (MH "Thoracic Surgery+") OR (MH "Pneumonectomy") OR (MH "Referral and Consultation+") OR (MH "Patient Admission") AND "Diagnostic timelines" OR (MH "Early Detection of Cancer") OR "early detection of cancer" OR (MH "Diagnosis, Delayed") OR "delayed diagnosis of cancer" OR "health system delay" OR "timeliness" OR "timeliness in healthcare" OR "timeliness of care" OR "patient delay" OR "patient interval" OR "Physician delay" OR (MH "Treatment Delay") OR "diagnostic delay" OR "diagnostic evaluation" OR "time to treatment" OR "treatment initiation" OR (MH "Waiting Lists") OR "wait* times" OR (MM "Appointments and Schedules") OR "prognostic implication" OR "lung cancer survival" Limiters - English Language; Published Date: 19990101-20190528; Human

Table 1: Timeliness definition and timepoints identified

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
1	Alexander et al 2016 Australia	Position paper	Recommendations for the timely triage, review and treatment of cancer patients receiving systemic chemotherapy for six priority cancer groups (breast cancer, colorectal cancer, lung cancer (non-small-cell and small cell), ovarian cancer, lymphoma and myeloma)						The first medical oncology or haematology review for patients with an urgent presentation (Category 1) should occur immediately, within no longer than 48 h of referral receipt. Patients with suspected cancer, not classed as Category 1 or 2 (Category 3), should be seen in a medical oncology or haematology clinic within 14 days of referral receipt as recommended by existing local and international guidelines.			When chemotherapy is the first anti-cancer treatment for a patient, time to chemotherapy should be measured from the date that chemotherapy treatment was decided and the patient was prepared to receive chemotherapy (ready for care) to the date when chemotherapy was first administered (chemotherapy start date). However, in the setting of adjuvant chemotherapy, time to chemotherapy should be measured from the date of surgery.	
2	Ampil et al 2014 USA	Cross sectional	Evaluating the types of delay in the management of people with SVCO-L Ca and the impact of palliative thoracic radiotherapy (PTR) delay on patient outcomes.										
3	Barrett & Hamilton 2008 UK	Nested retrospective case-control study	Aimed at identifying and quantifying clinical features of lung cancer										
4	Baughan et al 2009 UK	Cross sectional	The aim of this study is to gain a better understanding of how quickly patients with cancer initially present to their GP, and how they are then referred to secondary care for further investigation and treatment.		Date patient first noticed symptoms	Date patient first reported symptoms to primary care		Date of decision to refer	Date patient first seen by specialist		Date patient told the diagnosis		
5	Bjerager et al 2006 Denmark	Population based observational case series	To explore diagnostic delay in primary health care among patients with lung cancer.	Delay in general practice: the time from the patient's presentation of the first symptoms or signs that could be related to the lung cancer until referral to hospital. Delay in general practice was subdivided into: doctor delay: time elapsed without investigation of cancer-related symptoms and signs. System delay: time elapsed due to waiting times related to investigation of cancer-related symptoms and administration.									
6	Borrayo et al 2016 USA	Mixed Method	To better understand the institution- and the patient-level determinants associated with the timely initiation of cancer treatment among underserved Hispanic patients diagnosed with lung and head and neck cancers.										
7	Bozcuk & Martin 2001 UK	Retrospective medical record review	to analyse survival in relation both to time to treatment (hospital delay) and other known prognosticators, in a cohort of NSCLC patients presenting in 1 year in a UK Hospital with thoracic surgery and clinical oncology departments.										

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
8	Brocken et al 2012 Netherlands	Retrospective medical record review	To compare various delays in a rapid outpatient diagnostic program (RODP) for suspected lung cancer patients with those described in literature and with guideline recommendations, to investigate the effects of referral route and symptoms on delays, and to establish whether delays were related to disease stage and outcome.	Timeliness of lung cancer care starts with timely recognition of symptoms by patients themselves, which is often inadequate or delayed									
9	Buccheri & Ferrigno 2004 Italy	Retrospective medical record review	1) provide a more recent profile of the clinical manifestations of lung cancer; 2) evaluate possible time-related changes in the occurrence of symptoms; and 3) explore the possible relationship between symptoms and time to specialist referral.										
10	Bullard et al 2017 USA	Retrospective medical record review	To evaluate the impact that the initiation of timely treatment has on patient survival among a cohort of privately insured patients with NSCLC in South Carolina	Analysis of treatment timeliness was informed by the Andersen and Cacioppo model of delays in seeking cancer care.16 Delay in seeking cancer care is defined as the number of days from the identification of the first symptom to visiting a physician, being diagnosed as having a condition, or beginning a regimen for treating the condition. The model interprets delay as an aggregate of underlying decision-making processes imposed by the patient. Treatment delay is the time between receiving medical attention and when care or treatment is initiated.Timely care was defined according to the RAND Corporation as a maximal time limit of 6 weeks (≤42 days) from diagnosis to treatment.									
11	Corner et al 2004 UK	Exploratory study	To explore the pathway to diagnosis among a group of patients recently diagnosed with lung cancer.		Symptoms were recalled as having started between 4 months and more than 2 years	timing of their visits to the GP	Date of diagnosis						
12	Devbhandari et al 2007 UK	Prospective Cohort	To compare our waiting times with national recommendations										
13	Devbhandari et al 2008 UK	Prospective Cohort	To ascertain the causes of delays in treatment to all patients presenting to our centre with a working diagnosis of lung cancer										
14	Dobson et al 2017 UK	Qualitative study	to explore the patient intervals of people with symptoms of lung or colorectal cancer, considering how symptom appraisal and help-seeking experiences were influenced by the wider context of people's lives, such as family and work.		The date of symptom onset was defined as the first symptom reported	The end of the patient interval was defined as the date on which they consulted about their symptoms.							
15	Ellis & Vandermeer 2011 Canada	Cross sectional	Our objective was to establish the time delays in each phase to help inform strategies to reduce overall diagnostic delays.										

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
16	Emery et al 2013 Australia	Mixed methods study	The overall objective of this study was to identify the major subcomponents of the diagnostic interval for rural cancer patients in WA to inform the design of an intervention aimed at reducing time to diagnosis.										
17	Evans et al 2016 Australia	Retrospective cohort study	To assess factors associated with second-line delays in the management of patients diagnosed with lung cancer										
18	Ezer et al 2017 Canada	Cross sectional	The aim of the study was to assess the impact of this model of care (Rapid Investigation Clinic) on timeliness of lung cancer diagnosis , staging and treatment.										
19	Forrest et al 2014 UK	Population-based, data-linkage study	To investigate the factors (socioeconomic position (SEP), age, sex, histology, co-morbidity, year of diagnosis, stage and performance status (PS)) that may influence the likelihood of post-primary care referral, diagnosis and treatment within target times.										
20	Kanarek et al 2014 USA	Retrospective cohort	Evaluated the hypothesis that delay to first surgery and other time-related factors reduce survival after treatment (surgery). Then assessed the hypothesis that age, race, gender, place of residence, tumor characteristics, and morbidity confound the relationship between these factors and survival.										
21	Kim et al 2016 Canada	Retrospective medical record review	The aim of this study was to quantify the time intervals that NSCLC patients in Alberta with stage IeIII disease spend waiting for diagnosis (diagnostic interval), treatment (treatment interval) and their sum (system interval) and to determine which factors are associated with delays.										
22	Koyi et al 2001 Sweden	Cross sectional	The aim of the present study was to prospectively investigate a material of lung cancer patients in order to measure the delays, both by the patient and by the doctors.										
23	Kudjawu et al 2016 France	Retrospective medical record review	To describe time delays in each phase of lung cancer treatment after bronchoscopy.										
24	Largey et al 2015 Australia	Pilot study.	The audit was conducted as part of routine cancer quality improvement activities at Southern Metropolitan Integrative Cancer Services.			Dates of first presentation as the time point the clinician started investigation or referral for possible investigation		Referral	First specialist appointment	Diagnosis		Referral.	

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
25	Largey et al 2016 Australia	Retrospective medical record audit	(1) examine the current interval times for lung cancer patients from the point of initial referral to the start of first treatment at three large public principal referral hospitals in Victoria; (2) assess the effects difference treatment type (surgery, radiotherapy and chemotherapy) and health service had on interval times across the selected components of the lung cancer pathway; and (3) compare interval times and identify the proportion of patients who met the established target measures.										
26	Lee et,al. 2002 UK	Retrospective medical record audit	assessed the delays in their care against BTS guidelines.										
27	Li et al 2012 Canada	Retrospective medical record review	The purpose of this study was to assess the value in measuring specific time intervals across cancer sites to identify potentially important variation in the timeliness of cancer care that may inform needed changes and/or improvements incoordination of care.							dates of diagnosis			first treatment, surgery and adjuvant treatment.
28	Maiga et al 2017 USA	Retrospective cohort study	Investigation of the reasons for delays in treatment and the impact these delays have on tumor-stage progression.										
29	Malalasekera et al 2018 Australia	Scoping review	1) synthesise health system related waiting times to milestones of lung cancer care using standardised definitions; 2) benchmark measures of performance against relevant guidelines for timeframes; 3) supplement quantitative findings with barriers to timely care described in the literature; and 4) explore the impact of facilitators such as fast-track referral systems on waiting times.			First clinical presentation	First suspicious investigation	First referral to secondary care	First specialist visit	Diagnosis			Treatment start
30	Melling et al 2002 UK	Cross sectional	The purpose of this study was to find out what proportion of patients are referred as lung cancer guidelines assume, whether different referral pathways result in different management and what proportion of patients are seen within recommended time intervals between referral and treatment.	Definitive treatment was defined as surgery (pneumectomy or lobectomy), radical radiotherapy (radiotherapy directed at treating lung cancer itself) and chemotherapy. Palliative treatment recorded was palliative radiotherapy (for symptom control only), palliative surgery or best supportive care.	Symptom	Presentation	Diagnosis	referral					treatment
31	Neal et al 2015 UK	Mixed method	aims to provide a detailed analysis of the diagnostic process of lung cancer from a primary-care perspective.		Onset of first symptom	face-to-face consultations, nurse consultations, telephone consultations, out of hours, home visits before initial referral or investigation request First presentation to primary care	Date of diagnosis CXR requested CXR report received Diagnosis	Referral or admission					

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
32	Girolamo et.al. 2018 England	Retrospective medical record review	To assess the association between meeting waiting time targets, as currently available to the policymakers, and individual patients' cancer survival, and measure the time to different types of treatments.	Maximum two-week wait (TWW) between an urgent referral for a suspicion of cancer from a general practitioner (GP) to being seen by a specialist, a maximum 62 days from the referral to the start of the first treatment, and a maximum 31 days from the decision taken to treat a patient to the start of the first treatment, irrespective of the route to diagnosis the patient went through .									
33	Gozalez et.al. 2014, Spain	Retrospective medical record audit	To analyse the delays in the diagnosis and treatment of LC and the factors associated with the timeliness of care and their possible relationship with the survival of these patients										
34	Grunfeld et al 2009 Canada	Cross sectional	To prospectively measure peri-diagnostic and surgical time intervals for patients with suspected colorectal, lung, or prostate cancer				date of the pathology or radiology report	the date the referral for diagnostic assessment was received by the consultant		date of first relevant investigation initiated by consultant, whichever came first; relevant investigations included biopsy, bronchoscopy, chest X-ray, colonoscopy, sigmoidoscopy, CT scan, MRI, PSA, pulmonary function test, transrectal ultrasound, and other	date patient informed of diagnosis		date of initiation of first treatment (first treatment was definedas neoadjuvant chemotherapy, surgery if no preoperativetreatment was required, chemotherapy, radiotherapy, or a decisionfor no treatment
35	Helsper et al. 2017 Netherlands	Retrospective medical record review	To chart the diagnostic pathway for the five most common cancers in the Netherlands			The date of the first cancer-related GP consultation was defined as the first contact (physical or telephone) with the GP for suspected cancer-related signs or symptoms		The date of referral was defined as the moment when the responsibility for the patient was transferred from a GP to secondary care			the date of diagnosis was the date of the histological confirmation of the primary tumour.		The date of treatment initiation denotes the date of start of therapy as registered in the NCR
36	Hsieh et al 2012 Taiwan	Retrospective medical record review	To understand the delay in the diagnosis of lung cancer under the healthcare system in Taiwan, and to identify the factors associated with it										
37	Hubert et al 2018 Canada	Retrospective medical record review	To measure the timeliness of care with a standardized Rapid diagnostic assessment programs (DAP) in patients with early-stage non-small cell lung cancer (NSCLC) and to evaluate the impact of an ERP (enhanced recovery protocols) in these patients.										

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
38	Heredia et al 2012 Spain	Cross sectional	To analyze the results obtained in a lung cancer (LC) screening program since its inception five years ago regarding correct referrals, diagnostic and therapeutic delay times and days of hospitalization. To compare the diagnostic–therapeutic delays and hospital stays with those obtained in patients evaluated with the standard system										
39	Iachina et al 2017 Denmark	Retrospective cohort study	To investigate the significance of primary investigation and treatment at two or more hospitals on the delay in Danish patients with Non-Small Cell Lung Cancer (NSCLC).	** Time from referral (time of diagnosis) to end of primary investigation = 28 days **Time from referral (time of diagnosis) to first day of treatment = 42 days End of primary investigation is defined as the date of decision on treatment. Referral is defined as the date where the investigating department receives the referral.									First day of treatment is defined as the date of initiation of surgical, oncological, or radiological treatment, whichever comes first
40	Ju et al 2017 USA	Computer process modelling	To evaluate delays in care delivery, in order to identify potential 'bottlenecks' in waiting time, the reduction of which could produce greater care efficiency.										
41	Olsson et al 2009 USA	Systematic review	To summarise all recently published studies that described the timeliness of care in patients with lung cancer, identified factors that were associated with more or less timely care, or examined the association between the timeliness of care and lung cancer outcomes, including stage distribution and survival. In addition, we aimed to identify studies that evaluated interventions to improve the timeliness of care for patients with lung cancer.										
42	Ost et al 2013 USA	Guideline/review	This guideline is intended to provide an evidence-based approach to the initial evaluation of patients with known or suspected lung cancer. It also includes an assessment of the impact of timeliness of care and multidisciplinary teams on outcome.										
43	Özlü et al 2004 Turkey	Retrospective medical record review	To determine the delay between the onset and the diagnosis and treatment of patients with lung cancer in two cancer centres in the Eastern Black Sea Region of Turkey.		onset of symptoms	first presentation to a physician				histopathological diagnosis			start of treatment
44	Rankin et al 2017 Australia	Qualitative study	To describe the lung cancer diagnostic pathway, focusing on the perspective of patients and general practitioners about diagnostic and pretreatment intervals			first consultation with HCP	diagnosis						start of treatment

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
45	Rolke et al 2006 Norway	Cross sectional	to evaluate the delays in the diagnostic pathways for primary lung cancer in Southern Norway, and to compare results with recommendations from the British Thoracic Society (BTS) and the Swedish Lung Cancer Group (SLCG).	Patients referred by general practitioners, who have obvious clinical evidence of lung cancer, should be seen within 1 week of referral receipt in a respiratory physician's clinic, i.e. Referral delay. The results of bronchoscopy or any other similar diagnostic test, including the histological or cytological result, should be available and communicated to the patient within 2 weeks of a decision to do it, i.e. Informed diagnostic delay. Suspected lung cancer should wait no more than 1 week before they are investigated by a specialist, i.e. Referral delay. Diagnosed lung cancer should wait no more than 3 weeks since first specialist investigation to a treatment decision is made and no more than 10 days from a treatment decision was made until start of treatment, summarised as Hospital delay.									
46	Thapa et al 2014 Nepal	Cross sectional, prospective observational study.	To identify the steps through which the patients passed before he/she finally arrived to specialist care at Manmohan Cardiothoracic Vascular and Transplant Center (MCVTC) and also determine the time lost in each step.										
47	Verma et al 2018 Australia	Cross sectional	to identify any differences in time delays in lung cancer referral pathways between rural and urban patients and explore patients' perceived barriers to timely lung cancer diagnosis and management.										
48	Vidaver et al 2017 USA	Mixed method	This study explored when and why delays occur in lung cancer care and compared timeliness between two states with divergent disease incidence.	The RAND Corporation suggested that the diagnosis of lung cancer should be established within 2 months of abnormal radiography, and treatment should begin within 6 weeks of diagnosis. British Thoracic Society recommended that patients with suspected lung cancer be seen by a respiratory specialist within 7 days of referral; a specialist visit should occur within 2 weeks of an abnormal radiograph, and surgery should be within 8 weeks of a visit to a respiratory specialist.		A—first visit to health care provider with symptoms	B— first imaging result with a lung abnormality	C— referral to a specialist	D— first visit to a specialist	E— first diagnostic test F— last diagnostic test	G— patient informed of the biopsy result	H— first referral to treatment	I— first treatment
49	Wai et al 2012 Canada	A case-control study	The primary goal of this study is to investigate if delays in care may decrease the curability of patients with stage III NSCLC. The secondary goal is to describe the patterns of staging and diagnostic evaluation for palliatively and radically treated patients with stage III NSCLC in British Columbia.										

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
50	Walter et al 2015 UK	Prospective cohort study	To investigate the symptoms and other clinical and sociodemographic factors associated with lung cancer diagnosis, time to diagnosis and stage at diagnosis.	The total diagnostic interval (TDI), or 'time to diagnosis', defined as the time from the first symptom/s to the date of diagnosis.									
51	Wilcock et al 2016 UK	Mixed-methods	to identify areas where there may be potential to improve the care provided so as to inform the need for further focused research.										
52	Winget et al 2007 Canada	Stakeholders workshop	1) identify a set of criteria and variables needed to create comparable measures of important time-to-cancer-care intervals that could be applied across provinces and 2) use the measures to compare time-to-care across participating provinces for lung cancer patients diagnosed in 2004.										
53	Yang et al 2015 China	Case control	In this study, we determined the total time from the first symptoms to the initial treatment for lung cancer patients at the Department of Respiratory Disease of Zhongshan Hospital (Fudan University, Shanghai, China), a tertiary health care medical center	In China, a diagnosis delay for lung cancer has been defined as more than 1 month between the first symptom or radiological change and the clinical diagnosis or suspicion for lung cancer.	First symptom	First contact with local doctor		Referral to hospital		Diagnosis/ referral to treatment			Initiation of treatment
54	Yilmaz et al 2009 Turkey	Cross sectional	The aims of this study were to investigate the delays in patients with lung cancer from the first symptom to thoracotomy and to examine whether the delays affect the stage of lung cancer at the time of thoracotomy.	<p>The application interval that exceeded 30 days was considered indicative of a patient's delay.</p> <p>The interval that exceeded 14 days was considered indicative of a referral delay.</p> <p>The diagnosis interval that exceeded 14 days was considered as indicative of a delayed diagnosis.</p> <p>The interval that exceeded 14 days was considered as indicative of a delayed treatment.</p> <p>The interval that exceeding 6 weeks was considered as indicative of a doctor's delay.</p> <p>If exceeding 72 days it was considered indicative of a total delay</p>	date of initial symptoms	date of first doctor visit			date of admission to pneumology department of our hospital	date of diagnosis			date of thoracotomy
55	Yorio et al 2009 USA	Cross sectional	to examine the predictors and impact of the timing of lung cancer care in this context, we examined diagnostic and treatment intervals at a large American medical center providing care to a diverse patient population within two different hospital systems.	<p>Date of tissue diagnosis was defined as the date of final pathology report.</p> <p>Date of treatment was defined as the date of surgery, initial date of chemotherapy, or initial date of radiation therapy, whichever occurred first.</p>									
56	Zullig et al 2013 USA	Cross sectional	Aim 3: Examine patient-level factors associated with (a) receipt of timely lung cancer care and (b) subsequent health outcomes										
57	Sachdeva et al 2017 India	Cross sectional	To determine time delay from the onset of initial symptoms to diagnosis of primary lung cancer.										

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
58	Salomaa et al 2001 Finland	Retrospective medical record review	To measure delays of diagnosis and to assess the causes for those delays in patients with lung cancer. To evaluate whether the lengths of the delays were acceptable according to the British recommendations, and To examine the relations between delays and survival			the first symptoms until the first visit to a doctor, who was in general, a GP		the date the consultation request for a specialist was written	the first appointment with the specialist				
59	Sawicki et al 2013 Poland	Cross sectional	To compare the differences in the periods of time and reasons for delay in diagnosisand initiation of treatment of lung cancer among patients who are inhabitants of the rural and urban regions of LublinVoivodeship, and who were consulted in Thoracic Surgery Department										
60	Schultz et al 2009 USA	Cross sectional	To evaluate timeliness of lung cancer care and identify institutional characteristics associated with timely care within the Veterans Affairs (VA) health care system	British Thoracic Society guidelines) *Specialist visit within 2 wk of abnormal CXR *Surgery within 8 wk of specialist visit RAND guidelines *Diagnosis within 8 wk of abnormal CXR *Treatment within 6 wk of diagnosis							Time to diagnosis is the time from the first suspicious chest x-ray or CT scan to the date when a pathologic diagnosis of lung cancer was confirmed		
61	Shugarman et al 2009 USA	Cohort study	To evaluate the relationship of sex and race with the receipt of timely and clinically appropriate NSCLC treatment for each stage of diagnosis	Timely treatment as a 6-week timeframe from the date diagnosis to receipt of treatment (surgery, chemotherapy or radiation therapy)									
62	Singh et al 2010 USA	Cohort study	To evaluate characteristics and predictors of missed opportunities for earlier diagnosis of lung cancer in a health care system with an advanced integrated EHR		the first appearance of a diagnostic clue as the earliest date that the clue could have been recognized by the care providers, regardless of when the patient first started experiencing symptoms								
63	Smith et al 2009 Scotland	Cross sectional	To determine what factors are associated with the time people take to consult with symptoms of lung cancer, with a focus on those from rural and socially deprived areas		the date participant defined first symptom	date of presentation to a medical practitioner							
64	Sood et al 2009 NZ	Retrospective medical record review	To determine the patient characteristics, referral patterns and delays in assessment and treatment of patients with primary lung cancer in South Auckland, New Zealand and compare with international standards										

#	Author, pub date and country	Type/ design of study	Aim of study	Definition/ concept of timeliness in seeking care	Onset of symptom	First visit to healthcare provider	First imaging result with suspicion/ diagnosis	Referral to a specialist	First visit to a specialist	Invasive diagnostic test (e.g. FNAC, biopsy)	Patient informed of the biopsy result	Referral for treatment	Initiation of treatment
65	Stokstad et al 2017 Norway	Retrospective medical record review	To quantify the proportion of patients who started treatment within the recommended timeframes; and to assess the proportion of non-complex patients for which there were no good reasons for delays.	For suspected lung cancer, the first hospital appointment should be offered within seven calendar days of receiving a referral letter; a treatment decision should be made within 28 calendar days; systemic therapy should start within 35 calendar days, and surgery or radiotherapy within 42 calendar days. According to Norwegian recommendations, start of treatment within 42 days (surgery or radiotherapy) or 35 days (systemic therapy) was considered "timely treatment"				start time as the date when a referral letter for suspected lung cancer was received by the Department of Thoracic Medicine – or the date when the decision was made to start diagnostic workup in patients with a known single pulmonary nodule (SPN)					the time for treatment decision as the date when such a decision was documented in the EMR
66	Sulu et al 2011 Turkey	Cross sectional	To investigate patterns of delays among patients with non-small-cell lung cancer and to identify reasons for the delays.	**An application interval that exceeded 30 days was considered indicative of a patient's delay. **The referral interval that exceeded 14 days was considered indicative of a referral delay. **A diagnosis interval that exceeded 14 days was considered as indicative of a delayed diagnosis. **A treatment interval that exceeded 14 days was considered as indicative of a delayed treatment **Doctor's interval that exceeded 6 weeks was considered as indicative of a doctor's delay. ** Total interval exceeded 72 days was considered indicative of a total delay									
67	Chandra et al 2009 India	Retrospective review	To determine the average time period required at various steps for diagnosing lung cancer from the onset of symptoms at a tertiary referral centre in Northern India										
68	Dubey et al 2015 India	Cross sectional	The aim was also to study the time duration for confirming the diagnosis, the relative yield of the investigations in diagnosis of lung cancer and the lung cancer stage in which patients are presenting.										

Table 2: Intervals identified

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
1	Alexander et al 2016 Australia																								
2	Ampil et al 2014 USA								Patient delay was inferred from the duration of presenting symptoms until hospital admission		In-hospital delay was defined as the interval from the date of hospitalization to the date of referral for therapy		Professional delay was defined as the interval from the date of referral to first treatment												
3	Barrett & Hamilton 2008 UK						First symptom presented to primary care to diagnosis						Interval between first presentation to primary care with a symptom of lung cancer and referral			Interval from referral to diagnosis	The intervals between first symptom presentation and diagnosis								
4	Baughan et al 2009 UK	time from patient first noticing symptoms to first presentation with a GP																Time from first presentation to time of referral							
5	Bjerager et al 2006 Denmark																	First symptom until referral to secondary care							
6	Borrayo et al 2016 USA																					Diagnosis to treatment initiation			

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
7	Bozcuk & Martin 2001 UK												Time to treatment (measure of hospital delay): time from receipt of referral letter from GP /referring physician to first treatment . Referral time (measure of referral delay): time from receipt of GP /referring physician referral letter to first appointment in Norfolk & Norwich Hospital. It actually is a component of time to treatment .												
8	Brocken et al 2012 Netherlands	Patient delay as the time from first symptom until the first visit to a GP	GP delay as the time between first GP visit and referral to a chest physician		referral delay as the time between referral (written or by phone) and first rapid outpatient diagnostic program (RODP) day	Diagnostic delay as the time between first RODP day and date of final (accurate) diagnosis															Therapeutic delay as the time between diagnosis and start of treatment.				
9	Buccheri & Ferrigno 2004 Italy													Referral delay was defined as the time interval between the occurrence of the first symptom of alarm (as reported by the patients and confirmed by their relatives) and the date of the first specialist referral made to the study group). (normally made to the											

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
															study group).										
10	Bullard et al 2017 USA																								
11	Corner et al 2004 UK	Time between first change in health status and onset of symptom that prompted patient to visit GP or other service Time between onset of symptom prompting patient to visit GP and date of visit to GP or other service					Visit to GP or other service and date of diagnosis										Time between first recalled change in health status and date of diagnosis								
12	Devbhandari et al 2007 UK		Urgent GP referral to date first seen in outpatient clinics was calculated by subtracting the date of urgent referral from the date first seen in chest outpatient clinics													Intervals for investigations such as bronchoscopy were calculated by subtracting the date of urgent GP referral from the date of investigation				GP referral to date of first definitive treatment was calculated by subtracting the date of urgent GP referral from the date of commencement of the first definitive treatment.					
13	Devbhandari et al 2008 UK																					The intervals from outpatient to decision-to-treat	Decision-to-treat to treatment		
14	Dobson et al 2017 UK																								

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis's'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment	
15	Ellis & Vandermeer 2011 Canada	T1: time from initial symptoms to first presentation to a family doctor or emergency department	T3: time from initial presentation to the first appointment with a specialist, either directly to the JCC or to a respirologist or thoracic surgeon		T5: Time from JCC referral to initial consultation	T4: time between the initial appointment with the specialist and the last date of additional diagnostic testing	T2: time from initial presentation to the last date of diagnostic testing ordered by the family physician			T6: time from initial contact with a medical or radiation oncologist to the starting date of treatment, defined as chemotherapy, radiation therapy, or the decision not to pursue treatment															T7: Overall time from onset of symptoms to commencement of definitive therapy was also calculated as a global delay	
16	Emery et al 2013 Australia		Fist presentation in general practice to referral (GP interval)	From date of referral to fist attendance at specialist (specialist access interval)		Time from fist attendance at the specialist to date of diagnosis (specialist interval)	The diagnostic interval is the time from fist presentation until cancer diagnosis										Total diagnostic interval was defied as the time from fist symptom to diagnosis.									
17	Evans et al 2016 Australia															Referral to diagnosis				Referral to initial definitive management		Diagnosis to initial definitive management				
18	Ezer et al 2017 Canada	time interval (in days) between first contact with a local physician for suspected lung cancer (T0)					time interval (in days) between first contact with a local physician to date of tissue diagnosis														Time interval (in days) between first contact with a local physician to date of first treatment					
19	Forrest et al 2014 UK		GP referral date to first hospital appointment date			First hospital appointment date to diagnosis date	GP referral date to diagnosis date														GP referral date to first treatment date	Diagnosis date to first treatment date				
20	Kanarek et al 2014 USA							Time from diagnosis to first contact at SKCCC was defined as the referral interval.					Time from first contact at SKCCC to first surgery is defined as the treatment interval									Diagnosis to first surgery interval				

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
21	Kim et al 2016 Canada											Diagnostic imaging interval: From Date of the chest X-ray which preceded the last computed tomography scan prior to the first diagnostic biopsy attempt to Date of the last computed tomography scan prior to the first diagnostic biopsy attempt Diagnostic biopsy interval: From Date of the last computed tomography scan prior to the first diagnostic biopsy attempt to Date of the diagnostic biopsy procedure which provided pathological diagnosis										System interval: From Date of the chest X-ray which preceded the last computed tomography scan prior to the first diagnostic biopsy attempt to First day of treatment Treatment interval: From Date of diagnostic biopsy procedure which provided pathological diagnosis to First day of treatment			
22	Koyi et al 2001 Sweden	the patient's delay is the time from the first symptom(s) until the date he /she visits the doctor, in general the GP	GP delay, from the time a visit was arranged with the GP until the patient was referred to the specialist			specialist's delay (Second doctor's delay) is the time from when the lung specialist received the referral papers until the diagnosis was made.											Time symptom-diagnosis								Time symptom-treatment
23	Kudjauw et al 2016 France																								
24	Largey et al 2015 Australia																								
25	Largey et al 2016 Australia															Referral to-diagnosis				Referral-to-treatment		Diagnosis-to-treatment			
26	Lee et.al. 2002 UK																Onset of symptoms and their first chest radiograph	Onset of symptoms and referral to a surgeon by a chest physician							
27	Li et al 2012 Canada																					Time from diagnosis to first treatment			

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
28	Maiga et al 2017 USA																				The interval between T2 and T3 is the diagnosis-totreatment interval for patients with a tissue diagnosis before resection.				
29	Malalasekera et al 2018 Australia		Primary care interval				Diagnostic interval													Secondary care interval		Treatment interval			
30	Melling et al 2002 UK			Referral by GP to first seen by specialist				1 week of a CXR request to first hospital visit													First visit to any treatment				
31	Neal et al 2015 UK	'Patient interval' (time from symptom onset to presentation)					Date of request of first GP-initiated chest X-ray and date report received																		
32	Girolamo et.al. 2018 England			urgent referral for a suspicion of cancer from a general practitioner (GP) to being seen by a specialist																			The decision taken to treat a patient to the start of the first treatment		
33	Gonzalez et.al. 2014, Spain	from the first symptom to the first specialist consultation (specialist delay)				from the first specialist consultation until confirmation of the diagnosis (diagnosis delay)														From the first specialist consultation until the start of treatment (hospital delay)	From the confirmation of the diagnosis up to the start of the first treatment (treatment delay)				

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
34	Grunfeld et al 2009 Canada			Date of referral to date of first diagnostic consultation											Date of referral to date of confirmed diagnosis				Date of referral to date of initiation of first treatment (first tx was defined as neoadjuvant chemotherapy, surgery if no preoperative treatment was required, chemotherapy, radiotherapy, or a decision for no tx						**Date the referral for diagnostic assessment was received by the consultant ('date of referral') to date patient informed of diagnosis ** Date of first diagnostic consultation to date patient informed of diagnosis **Date of referral to date of surgery or decision for no surgery ** Date of confirmed diagnosis to date of surgery or decision for no surgery **Date of referral to date of surgery**Date of surgery to date of first oncology consultation or decision for no consultation
35	Helsper et al. 2017 Netherlands		the time between the first cancer symptom related contact with the general practitioner (GP) and its corresponding referral to secondary care (Primary care interval (ICP))				the time from the first presentation to the GP to diagnosis (diagnostic interval (ID))								The time from referral to histological diagnosis (referral interval (IR))					The time from the first presentation to the GP to initial treatment (health care interval (IHC))	The time from diagnosis to initiation of the treatment (Treatment interval (IT))				
36	Hsieh et al 2012 Taiwan																								Delay in diagnosis' has been defined as the period from a patient's initial medical visit to any hospital to his/her confirmed diagnosis of lung cancer

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
37	Hubert et al 2018 Canada																								**The first one was the interval between the moment that the green file was opened until all lung cancer staging and clinical tests were performed, and patient was referred for surgery after discussion with the respirologist **The second interval was the time between the referral to the thoracic surgery department the consult with the surgeon ** The last interval was from the surgical consult to the date of surgery
38	Heredia et al 2012 Spain																								
39	Iachina et al 2017 Denmark																						Time from end of primary investigation to first day of treatment = 14 days		
40	Ju et al 2017 USA																								
41	Olsson et al 2009 USA			from referral to first respiratory specialist visit																GP referral to initial treatment		from diagnosis to treatment		specialist consultation to surgery	symptom onset to initial treatment
42	Ost et al 2013 USA																					Diagnosis to treatment			

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
43	Özlü et al 2004 Turkey	From first symptom to presentation				admission and tissue diagnosis	From presentation to tissue diagnosis														From presentation to first treatment	From diagnosis to treatment			From symptoms to treatment
44	Rankin et al 2017 Australia						The diagnostic interval is defined as "the time between first appointment with a health-care provider (HCP) and the formal cancer diagnosis being made."															The pretreatment interval is defined as "the time between formal cancer diagnosis and initiation of treatment"			
45	Rolke et al 2006 Norway	Patient delay: Time from first symptom to first personal contact with doctor	GP delay: Time from first contact with general practitioner (GP) to date on written referral.	Referral delay: Time from dated referral receipt to first contact with pulmonary consultant.		Specialist delay: Time from first contact with pulmonary consultant to dated diagnostic histology/cytology																	Hospital delay: Time from first contact with pulmonary consultant to start of treatment.	Total delay: Time from first symptom to start of treatment.	
46	Thapa et al 2014 Nepal	D1=Time from onset of symptoms to first contact with a doctor (T1-T2) or patient delay					D2=Time from first contact with doctor to referral to MCVTC (T2-T3) or doctor delay																		
47	Verma et al 2018 Australia	T2: Time between first symptoms to first GP consultation	T3: Time between GP and specialist consultation							T4: Time between specialist consultation and commencement of treatment.															T1: Time from first symptoms to commencement of treatment.
48	Vidaver et al 2017 USA		Initial presentation-specialist referral	Specialist referral-specialist consultation			Initial presentation-confirmed diagnosis			Specialist consultation-treatment											Initial presentation-treatment	Abnormal radiograph-treatment Confirmed diagnosis-treatment		Treatment consultation-treatment	

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
49	Wai et al 2012 Canada							Diagnosis is to cancer centre referral Diagnosis is to radiation oncology consult									First symptom to diagnosis							Radiation oncology consult to start of radiation treatment	
50	Walter et al 2015 UK																'time to diagnosis' , defined as the time from the first symptom/ sto the date of diagnosis								
51	Wilcock et al 2016 UK																						time from lung cancer MDT treatment recommendation to commencement of an 'active' oncological treatment		
52	Winget et al 2007 Canada																					1) diagnosis to first treatment in a cancer facility (that is, radiation or chemotherapy)		3) first consult with an oncologist to first treatment in a cancer facility.	
53	Yang et al 2015 China	Patient delay: First symptom to first contact with a local doctor	Delay in primary care: first contact with a local doctor to referral to hospital													Diagnostic delay in secondary healthcare: referral to hospital to diagnosis				Delay in secondary health care: referral to hospital to initiation of treatment	System delay: First contact with a local doctor to initiation of treatment	Treatment delay: Diagnosis to initiation of treatment			
54	Yilmaz et al 2009 Turkey	patient's application interval was defined as the time passed between the onset of symptoms and the first doctor visit.	The referral interval was defined as the time from the first doctor visit to admission to one of the pneumology departments of our hospital for the further investigation																		Doctor's interval was defined as the time from the first doctor visit to thoracotomy	The treatment interval was the time passed from the diagnosis to thoracotomy			The total interval was the time between the onset of symptoms and thoracotomy
55	Yorio et al 2009 USA																					diagnosis to treatment.			

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
56	Zullig et al 2013 USA							Days from diagnosis to referral to palliative care or hospice														Days from diagnosis to initiation of treatment			
57	Sachdeva et al 2017 India																Delay in diagnosis from the onset of initial symptoms to histological confirmation								
58	Salomaa et al 2001 Finland		Patient's delay is the time from the first symptoms until the first visit to a doctor, who was in general, a GP	GP delay, which is the time from the date the patient visited the first doctor until the date the consultation request for a specialist was written	The referral delay is the time between the writing of the referral and the first appointment with the specialist		The specialist's delay is the time from the first appointment until the diagnosis was made															The treatment delay is the time from the diagnosis until the treatment began			symptom-to-treatment delay
59	Sawicki et al 2013 Poland	Time from the first signs of the disease to the first medical examination																			the time from the first visit to a doctor to the start of treatment, or disqualification from the causative treatment				
60	Schultz et al 2009 USA	Time to treatment was the time from the first suspicious radiograph to the date on which any treatment was first initiated ** In patients who refused treatment, we used the date of refusal as the endpoint for time to treatment																							
61	Shugarmann et al 2009 USA	first date recorded for treatment																							
62	Singh et al 2010 USA																								

#	Author, pub date and country	Symptom to doctor/ GP	GP to LCS/ Chest clinic/ referral/ GP to first hospital appointment/ admission	Referral to first attendance to specialist	Chest clinic to referral for Chest Physician	Chest Physician/ hospital appointment to Diagnosis	GP to diagnosis	Diagnosis to referral to LCS/ or hospital	Symptom to hospital admission	LCS to treatment	Hospitalization to treatment referral	Diagnostic intervals (imaging/ biopsy)	Referral for treatment to initiation of treatment	Symptom to 'referral for diagnosis'	Symptom to referral to LCS	Referral for diagnosis' to diagnosis	Symptom to diagnosis	Symptom to referral (by GP or chest physician to next Mx)	Symptom to secondary care	Referral to treatment	GP to treatment	Diagnosis to initiation of treatment	Outpatient to decision to treat	Decision to treat/ specialist consultation to treatment	Symptom to initiation of treatment
63	Smith et al 2009 Scotland	The number of days from date of first symptom defined by the participant until date of presentation of symptoms to a medical practitioner																							
64	Sood et al 2009 NZ																								
65	Stokstad et al 2017 Norway																								
66	Sulu et al 2011 Turkey		Patient's application interval was defined as the time elapsed from the onset of symptoms to the first doctor's visit		The referral interval was defined as the time from the first doctor's visit to admission to our hospital for the further investigation.		The diagnosis interval was regarded as the time elapsed from admission to our hospital to the pathological diagnosis.														Doctor's interval was defined as the time elapsed the first doctor's visit to treatment	The treatment interval was the time elapsed from the diagnosis to treatment			The total interval was the time elapsed from the onset of symptoms to treatment
67	Chandra et al 2009 India																symptom-to-diagnosis delay, between the onset of symptoms to confirmed diagnosis					diagnosis-to-treatment delay, between diagnosis and treatment started			symptom-to-treatment delay, between onset of symptoms and treatment
68	Dubey et al 2015 India																The onset of symptoms to the confirmation of diagnosis								

Table 3: Other uncommon timepoint and intervals

#	Author, pub date and country	Other time point or Intervals
1	Alexander et al 2016 Australia	NSCLC: Where systemic chemotherapy is the first anti-cancer treatment modality, in either definitive or palliative treatment settings, chemotherapy should commence within 3 weeks of the ready for care date (level III, grade C †). Adjuvant chemotherapy should commence as soon as the patient is medically fit following surgery and within 8 weeks of the date of surgery (level III, grade C †). SLC: Patients with severe or life-threatening symptoms should be regarded as a medical emergency and chemotherapy initiated immediately, within no longer than 48 h ± of the ready for care date – hospitalisation may be required (good practice point †). All other patients should commence chemotherapy within 2 weeks of the ready for care date (good practice point †)
12	Devbhandari et al 2007 UK	GP referral to chest outpatient GP referral to decision to treat GP referral to treatment Oncology referral to chemotherapy Waiting on surgical waiting list Oncology referral to radiotherapy
23	Kudjawu et al 2016 France	1) from bronchoscopy to: (a) first neo-adjuvant chemotherapy, (b) first combined neo-adjuvant radiotherapy chemotherapy, (c) surgery, (d) first chemotherapy (in patients who underwent chemotherapy only), (e) first radiotherapy (in patients who underwent radiotherapy only), (f) first treatment (irrespective of treatment type);2) from last neo-adjuvant chemotherapy to surgery; 3) from last combined neo-adjuvant radiotherapy-chemotherapyto surgery; 4) from surgery to: a) first chemotherapy, and b) first radiotherapy.1- Patients with surgical pathwayTime from bronchoscopy to surgery, Time from bronchoscopy to first neo-adjuvant chemotherapy, Time from bronchoscopy to first neo-adjuvant radiotherapy (combined to chemotherapy), Time from surgery to first chemotherapy, Time from last neo-adjuvant chemotherapy to surgery 2- Patients with non-surgical pathwayTime from bronchoscopy to first chemotherapy, Time from bronchoscopy to first radiotherapy 3- Treatment combinationTime from bronchoscopy to first treatment, Time from bronchoscopy to surgery as first treatment, Time from bronchoscopy to surgery as only treatment, Time from bronchoscopy to first chemotherapy as only treatment, Time from bronchoscopy to first radiotherapy as only treatment, Surgery followed by chemotherapy, Time from bronchoscopy to surgery, Time from surgery to first chemotherapy, Surgery followed by radiotherapy, Time from bronchoscopy to surgery, Time from surgery to first radiotherapy Chemotherapy followed by surgery and chemotherapy, Time from bronchoscopy to first neo-adjuvant chemotherapy, Time from last neo-adjuvant chemotherapy to surgery, Time from bronchoscopy to surgery, Surgery followed by chemotherapy and radiotherapyTime from bronchoscopy to surgery, Time from surgery to first chemotherapy, Time from surgery to first radiotherapy
26	Lee et,al. 2002 UK	interval between referral by a respiratory physician and surgical out-patient attendance between referral by a respiratory physician and the surgical procedure time from surgical out-patient attendance to the surgical procedure
27	Li et al 2012 Canada	Time from surgery to post-surgical treatment. Time from surgery to consultation with an oncologist.
28	Maiga et al 2017 USA	Timepoints: Time zero (T0) is the date of lung nodule identification on computed tomography (CT) imaging according to the medical record; T1 is the date when a lung nodule originally less than 10 mm in size was documented as having new growth on CT imaging. T2 is the date of pathology diagnosis. T3 is time of resection and final pathology diagnosis. Intervals: Date of lung nodule identification on CT (T0) or date when a lung nodule originally less than 10 mm (T1) to time of resection and final pathology diagnosis (T3) is the time-totreatment interval.
29	Malalasekera et al 2018 Australia	Doctor interval: First clinical presentation to First suspicious investigation System interval: First suspicious investigation to Treatment start
38	Heredia et al 2012 Spain	**Interval in days between the 1st evaluation and staging **Interval in days between the first evaluation and the start of treatment **Interval in days between the referral date and staging **Interval in days between the staging date of the tumor and the start of treatment **Therapeutic delays in days since the first evaluation : Interval until surgical treatment, Interval until the start date of oncologic treatment, Interval until the start date of palliative treatment
39	Iachina et al 2017 Denmark	** Time from referral (time of diagnosis) to end of primary investigation = 28 days **Time from referral (time of diagnosis) to first day of treatment = 42 days **End of primary investigation is defined as the date of decision on treatment. Referral is defined as the date where the investigating department receives the referral.
40	Ju et al 2017 USA	1. initial radiologic lesion detection by chest x-ray or CT scan (Step 1) tp diagnostic biopsy (Step 2), 2. diagnostic biopsy (Step 2) to radiologic staging (Step 3), 3. radiologic staging (Step 3) to invasive staging (Step 4), 4. invasive staging (Step 4) to surgery (Step 5). 5. initial radiologic lesion detection by chest x-ray or CT scan (Step 1) to radiologic staging (Step 3) 6. initial radiologic lesion detection by chest x-ray or CT scan (Step 1) to invasive staging (Step 4) 7. initial radiologic lesion detection by chest x-ray or CT scan (Step 1) to surgery (Step 5)
41	Olsson et al 2009 USA	Waiting list for surgery Decision-to-treat to treatment other than surgery
42	Ost et al 2013 USA	Suspicion to treatment
45	Rolke et al 2006 Norway	Informed diagnostic delay: Time from decision of doing a diagnostic procedure to informing patient of diagnosis.
46	Thapa et al 2014 Nepal	T1=Time since the onset of symptoms to assessment at hospital (MCVTC) T2=Time since fist contact with a doctor to assessment at Hospital T 3=Time since referral to MCVTC with suspicion of Lung Cancer
48	Vidaver et al 2017 USA	First diagnostic test-last test
49	Wai et al 2012 Canada	Driving times to the nearest cancer center at the time of diagnosis First symptom to first abnormal test First abnormal test to diagnosis
51	Wilcock et al 2016 UK	From emergency admission to diagnosis From emergency admission to discussion at the lung cancer MDT
52	Winget et al 2007 Canada	2) diagnosis to first consult with an oncologist
54	Yilmaz et al 2009 Turkey	The diagnosis interval was regarded as the time passed between the admission to our hospital and the pathological diagnosis was made.
55	Yorio et al 2009 USA	Survival time was defined as the interval between the date of treatment and the date of death or censoring. The intervals included in this analysis were image to diagnosis. Image to treatment
56	Zullig et al 2013 USA	Days from diagnosis to death
62	Singh et al 2010 USA	Two types of missed opportunities that could result in diagnostic delays: (1) type I missed opportunities, defined as episodes of care in which there was failure to recognize a predefined clinical clue (ie, no required action or work-up was initiated within 7 days of clue appearance); appropriate decisions to watch and wait were not considered missed opportunities; and (2) type II missed opportunities, defined as episodes of care in which there was failure to complete within 30 days a diagnostic procedure, consultation, or other requested follow-up action in response to a predefined clue.
63	Smith et al 2009 Scotland	Two definitions of first symptom were used—participant-defined and health professional defined—using a checklist of symptoms compiled from CancerResearch UK lung cancer symptoms and SIGN guidelines. **the number of days from date of earliest symptom from the symptom checklist until date of presentation of symptoms to a medical practitioner

#	Author, pub date and country	Other time point or Intervals
64	Sood et al 2009 NZ	<div>** postal delay (time taken to receive the referral at the outpatient clinic from the referrer)</div> <div>**grading delay (time taken to grade the referral)</div> <div>**clinic delay (interval between date of receiving referral and to date of patient assessment)</div> <div>**interval from initial chest physician assessment to bronchoscopy</div> <div>**interval from initial respiratory assessment to CT chest</div> <div>**interval from initial CT chest to CT-guided fine needle aspiration (CT FNA)</div> <div>** First respiratory assessment to final diagnosis</div> <div>**Date referral received to diagnosis achieved</div> <div>**Date of GP referral to first respiratory assessment</div> <div>**First respiratory assessment to surgery</div> <div>**Date referred to surgeons to surgery</div> <div>**Date of oncology referral to commencement of radiotherapy</div> <div>**Date of oncology referral to commencement of chemotherapy</div>
65	Stokstad et al 2017 Norway	<div>Timepoint:</div> <div>Start of treatment as date of surgery, first fraction of radiotherapy, first day of intra-venous chemotherapy, or date of prescription of oral cancer therapy.</div> <div>Time to start of treatment was defined as the number of calendar days from start time until start of treatment</div> <div>** time to treatment decision: start time to the date when such a decision was documented in the EMR</div>

Table: Measures of timeliness with cutoff values from different guidelines

Interval	Cutoff value	Guidelines	Naming of interval
Onset of symptoms to first doctor visit ^{28 51}	30 days	BTS	Patient's Application interval ^{28 51}
First clinical presentation to first suspicious investigation ^{35 80}	28 days	DLCG	
First abnormal investigation (CXR) to confirmation of diagnosis/specialist visit ⁴¹	14 days	BTS	
	56 days	RAND	
GP to Specialist ^{24 28 35-37 42 49 51 61 69 70 84}	1 day for urgent referrals, 10 days for standard referrals	IOM	Referral delay ⁴⁹ or Referral Interval ^{28 51}
	80% within 3–5 days	ACCP, DLCG, DAPPDT	
	7 days	BTS, NICE, NNG	
	14 days	UKNHS, Australian, UKDoH, SIGN, SMAC, CSCC, SLCG	
Primary care to initiation of treatment ^{28 35 42 51 63 67 68 77}	14 days	DLCG	System interval ³⁵ or Doctor's interval ^{28 51}
	42 days	SLCG, CSCC	
	62 days	UKNHS, UKNCP, BTS, Joint Council for Clinical Radiology	
	98 days	RAND	
	28 days for treatment decision, 35 days for systemic therapy 42 days for surgery or radiotherapy	Norwegian National Guidelines	
Referral to secondary care to Diagnosis ^{28 36 45 51 61 84}	28 days	UKDoH, CSCC, DLCG	Diagnosis Interval ^{28 51}
	14 days	BTS	
First referral to secondary care to treatment start ^{21 35 44 69-71 80}	42 days	Australian	Secondary care interval ³⁵
	49 days	NOLCP	
	62 days	UKNHS, SEHD, NICE, BTS	
	42 days in ≥85% patients	DLCG	
First clinical presentation to Diagnosis ^{35 84}	28 days	CSCC	Diagnostic interval ³⁵
	60 days	RAND	
First investigation to treatment ⁴⁵	14 days	DLCG	
Diagnostic investigation to patient informed of diagnosis ⁴⁹	7 days	BTS	Informed diagnostic delay ⁴⁹
Diagnosis to Treatment start ^{28 35 41 45-47 51 55 68 80 84 110}	14 days	Australian, DLCG	Treatment interval ^{28 35 51 55 68}
	14 days in ≥80% patients, 35 days if mediastinoscopy	SLCG, DAPPDT	or Therapeutic delay ⁴⁷
	14 days until surgery	CSCC	
	21 days	DLCG, DAPPDT	
	28 days	NOLCP	
	31 days	UKNHS	
	42 days for NSCLC/14 days for SCLC	RAND	
	42 days	DLCG, *Other study	

Interval	Cutoff value	Guidelines	Naming of interval
First clinical presentation to treatment start ^{24 34 35}	56 days for surgery	SMAC, UKDoH, SIGN,	Total interval ³⁵
	52 days	Cutoff value proposed by authors	
Decision to treatment to initiation of treatment ^{43 67 71 77}	21 days	UKNHS	
	31 days (28 days for surgery & radiotherapy, 7 days for chemotherapy)	UKNCP, BTS, Joint Council for Clinical Radiology	
Surgery to chemotherapy (Adjuvant chemotherapy) ⁴³	48 days	UKNHS	
Referral receipt to specialist consultation ^{21 43}	14 days	UKNHS, SEHD, NICE	
Oncology referral to radiotherapy/ chemotherapy ⁷⁰	14 days	BTS, NICE	
Specialist consultation to surgery ^{41 69 70 79}	56 days	BTS, NICE	
Surgeon consultation/Surgical waiting list to surgery ^{61 70 79}	28 days	BTS, NICE	
	14 days	CSCC, *Other study	
Onset of symptoms to treatment ^{28 51}	72 days	BTS, Canadian guidelines	Total interval ^{28 51}
Primary care referral to first diagnostic evaluation of symptom ³⁷	7 days	BTS	Type I missed opportunity (No evaluation or work-up was initiated within 7 days of appearance of a predefined clinical clue) ³⁷
Primary care referral to completion of evaluation at referral center ³⁷	30 days	BTS, *Other article	Type II missed opportunity (Failure to complete within 30 days a diagnostic procedure or consultation or the follow-up action requested in response to a predefined clue) ³⁷

*Cutoff value adapted from other studies. IOM: Institute of Medicine, CSCC: Canadian Strategy for Cancer Control, NHMRC: National Health and Medical Research Council, ACCP: American College of Chest Physicians, BTS: British Thoracic Society, UKDoH: United Kingdom Department of Health, UKNHS: United Kingdom National Health Service, NICE: National Institute for Health and Care Excellence, UKNCP: United Kingdom National Cancer Plan, SLCG: Swedish Lung Cancer Group, RAND: Research and Development USA, NOLCP: National Optimal Lung Cancer Pathway, SEHD: Scottish Executive Health Department, DLGG: Danish Lung Cancer Group, SMAC: Standing Medical Advisory Committee, SIGN: Scottish Intercollegiate Guideline Network, CCA: Cancer Council Australia, DAPPDT: Dutch Association of Physicians for Pulmonary Disease and Tuberculosis, NNG: Norwegian National Guidelines.